

CURRICULUM VITAE

1) Date of preparation of CV: October 14, 2020

2) Personal data:

a) Name: Gervasio Antonio Lamas, M.D.

3) Education: 06/1974; Biochemical Sciences B.A.; Harvard College

06/1978; M.D; New York University School of Medicine

4) Postdoctoral Training: 1978-1979; Medical Intern, Brigham and Women's Hospital

1979-1980; Junior Assistant Resident, Brigham and Women's Hospital

1980-1981; Senior Assistant Resident, Brigham and Women's Hospital

1979-1981; Clinical Fellow in Medicine, Harvard Medical School

1981-1983; Research/Clinical Fellow in Medicine, Brigham and Women's Hospital.

1981-1984; Research Fellow in Medicine, Harvard Medical School

5) Licensure/
Board Qualifications: New York State Medical License, 2009-
Certificate #7957092

Florida Board of Medicine, 1995-
Certificate #ME 0069106

Massachusetts License Registration, 1978-2000
Certificate # 46588

American Board of Internal Medicine
Certificate # 82864 issued on 9/16/81, active

American Board of Cardiology, 1983
Certificate # 82864 issued on 11/9/83, active

International Board of Heart Rhythm Examiners,
Testamur 1986

6) Military service: Not applicable

7) Professional organizations and societies:

Massachusetts Medical Society, 1986-present

Fellow, American College of Cardiology, 1986-present

Fellow, American Heart Association, 2007-present

Fellow, European Society of Cardiology, 2008-present

8) Academic Appointments: 1984-1988; Instructor in Medicine; Harvard Medical School

1988-1993; Assistant Professor of Medicine; Harvard Medical School

1993-2008; Associate Professor of Medicine at Mt. Sinai; University of Miami School of Medicine;

1999-2008; Director, Cardiovascular Research & Academic Affairs; Mount Sinai Medical Center

2008-2009; Voluntary Professor of Medicine, Miller School of Medicine, University of Miami

2008-2009; Cardiology Fellowship Program Director; Jackson Memorial Hospital/Miami VAMC/University of Miami Hospital

2008-2009; Interim Vice Chair for Clinical Affairs, Division of Cardiology; Miller School of Medicine, University of Miami

2009-2013; Professor of Clinical Medicine, Columbia University Division of Cardiology, College of Physicians and Surgeons, Mount Sinai Medical Center

2013- Present; Professor of Medicine, Division of Cardiology, Columbia University Medical Center

9) Hospital Appointments: 1983-1993; Associate Physician; Brigham and Women's Hospital

1986-1993; Director; Brigham and Women's Hospital, Pacemaker Clinic

1993-1999; Chief, Division of Cardiology; Mount Sinai Medical Center

1999-2008; Director of Cardiovascular Research and Academic Affairs; Mount Sinai Medical Center

2008-2009; Director, Coronary Care Unit; University of Miami Hospital

2009-present; Chief, Columbia University Division of Cardiology; Mount Sinai Medical Center

2009-present; Co-Director, Mount Sinai Heart Institute, Mount Sinai Medical Center

2011-Present; Chair of Medicine, Mount Sinai Medical Center

10) Honors:

Cum Laude - Biochemical Sciences, 1974

AOA Honor Medical Society, 1978

Samuel Spiegel Award for Excellence, New York University School of Medicine, 1978

Profesor Honorario de la Universidad del Salvador, Republica de Argentina, 2004

“Huesped de Honor” de la Facultad de Ciencias Médicas de la Universidad Nacional de la Plata, Argentina 2004

“Profesor Visitante” de la Facultad de Ciencias Médicas de la Universidad Nacional de la Plata, Argentina. 2004

Latino of the Year 2005 (Latin Business Club of America)

Norman Clarke Award from the American College for Advancement in Medicine for Advancing Research into Chelation Therapy, 2013

Distinguished Visiting Professor, HSRLCE Cardiovascular Scientific Day, Toronto, Canada, 2017

11) Fellowship and grant support (Federal Grants):

1. 1987-1992; Survival and Ventricular Enlargement- SAVE
Principal Investigator of the Brigham SAVE center and Catheterization Core Laboratory, Chairman, Forms Committee, Participant, Mortality and Endpoints Committee, Member, Clinical Coordinating Center.
Total Funds: \$580,000 Sponsor: Bristol-Myers Squibb
2. 1992-1993; Clinical evaluation of the Medtronic 4068 lead system

Status on grant:

Total Funds: \$30,000 Sponsor: Medtronic

3. 1990-1993; Cholesterol and Recurrent Events- CARE
Principal Investigator, Brigham CARE Center
Total Funds: \$400,000 Sponsor: Bristol-Myers Squibb
4. 1993-1995; Healing and Early Afterload Reducing Therapy- HEART
Principal Investigator at the HEART Catheterization Core Laboratory at Mount Sinai Medical Center Member, Planning Committee, Executive Committee
Total Funds: \$62,000 Sponsor: Hoechst Marion Roussel & Upjohn
5. 1993-1996; Pacemaker Selection in the Elderly-PASE
Principal Investigator and Study Chairman
Total Funds: \$600,000. Sponsor: Intermedics, Inc
6. 1994-1998; Rate Responsive Dual Chamber Study
Principal Investigator and Study Chairman
Total Funds: \$680,000. Sponsor: Pacesetter Systems, Inc.
7. 1995-2002; Mode Selection Trial in Sinus Node Dysfunction- MOST
Principal Investigator and Study Chairman
Total Funds at Mount Sinai Medical Center: \$12,358,000
Total Funds at Data Coordinating Center: \$15,000,000
Funding agency: National Heart Lung & Blood Institute
8. 1996-2001; Enhancing Recovery in Coronary Heart Disease Patients- ENRICH/Project II
Trial Director at Mount Sinai
Total Funds: \$550,000 Funding agency: National Heart Lung & Blood Institute
9. 1997- 1998; Grant to chair the NHLBI Clinical Trials Review Committee
Chairman
Total Funds \$150,000 Funding agency: National Heart Lung & Blood Institute
10. 1997-2002; The Prevention of Events with Angiotensin Converting Enzyme Inhibition-PEACE
Clinical Unit Principal Investigator
Total Funds: \$35,000 Funding agency: National Heart Lung & Blood Institute
11. 1998-2006; The Occluded Artery Trial- OAT
Co-Chairman
Total Funds \$15,000,000
Data Coordinating Center: \$15,000,000
Funding agency: National Heart Lung & Blood Institute

12. 1999-2002; Valsartan In Acute Myocardial Infarction- VALIANT
U.S. Consortium Co-Leader
Total Funds: \$100,000 Sponsor: Novartis Pharmaceuticals
13. 1999-2002; The Advanced Elements of Pacing Trial- ADEPT
Study Chairman
Total Funds: \$2,900,000 Sponsor: Medtronic
14. 1999-2003; Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity- CHARM
Clinical Unit Investigator- U.S. Leader (1 of 7).
Total Funds: \$120,000 Sponsor: AstraZeneca
15. 2000-2001; A randomized trial of effects of aspirin on C-reactive protein increases due to postmenopausal hormone therapy.
Principal Investigator and Study Chairman
Total Funds: \$ 300,000 Funding agency: Bayer Pharmaceuticals
16. 2001-2005; The Heart Failure Home Care trial- HFHC
Clinical Unit Investigator
Total Funds: \$450,000 Funding agency: Centers for Medicare & Medicaid Services
17. 2002-2014; Trial to Assess Chelation Therapy- TACT
Principal Investigator and Study Chairman
Total funds: \$31,652,717 Funding agencies: National Heart Lung & Blood Institute/ National Center for Complementary and Alternative Medicine
18. 2003-2008; Search AV Extension and Managed Ventricular Pacing for Promoting Atrio-Ventricular Conduction-SAVE-PACe
Study Co-Chair
Total Funds: \$2,000,000 Sponsor: Medtronic
19. 2005- present; Evaluation of the Safety and Efficacy of the Optimizer II System with Active Fixation Leads in Subjects with Heart Failure Resulting from Systolic Dysfunction- FIX-HF.
Clinical Unit Investigator
Total Funds: \$135,000 Sponsor: Impulse Dynamics, Inc.
20. 2009; Study to Evaluate the Safety and Efficacy of PROCHYMAL® (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction. OSIRIS 403
Clinical Unit Principal Investigator
Total Funds: \$120,000 Sponsor: Osiris Therapeutics, Inc.
21. 2009- 2010; Spirocor Coronary Outcome by Respiratory Stress Examination- SCORE.
Clinical Unit Co-Investigator
Total Funds: \$25,000 Sponsor: Spirocor, Inc.

22. 2009- 2011; A Phase 3, Randomized, Double-Blind, Evaluation of the Safety and Efficacy of Apixaban in Subjects with a Recent Acute Coronary Syndrome - APPRAISE-2.
Clinical Unit Principal Investigator
Total Funds: \$80,000 Sponsor: Bristol-Myers Squibb
23. 2011-present; A randomized, double-blind, placebo-controlled trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP- CANTOS
Clinical Unit Principal Investigator
Total Funds: \$116,000 Sponsor: Novartis
24. 2011-2013; Evaluation of the Safety and Efficacy of Short-term A 002 Treatment in Subjects with Acute Coronary Syndromes (VISTA-16)
Clinical Unit Principal Investigator
Total Funds: \$96,637 Sponsor: Anthera Pharmaceuticals
25. 2011-2015; A Randomized, Double-Blind, Placebo Controlled Trial, to Assess the Prevention of Thrombotic Events with Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients with History of Myocardial Infarction (PEGASUS-TIMI 54)
Clinical Unit Principal Investigator
Total Funds: \$95,800 Sponsor: Astra Zeneca
26. 2012-present; Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at a High-Risk for Vascular Outcomes- ACCELERATE.
Clinical Unit Principal Investigator
Total Funds: \$389,961 Sponsor: Eli Lilly
27. 2013-2014; Improving Syncope Risk Stratification in Older Adults.
Co-chair- Steering Committee
Total Funds: \$156,332
Sponsor: Oregon Health and Science University/ Collaborator: NIH
28. 2014-2016; James P. Carter Memorial Grant for EDTA Chelation Research
Principal Investigator
Total Funds: \$20,000
Sponsor: International College of Integrative Medicine (ICIM)
29. 2016-present; The Trial to Assess Chelation Therapy 2 (TACT2)
Principal Investigator and Study Chairman
Total Funds: \$38,935,277
Sponsor: NCCIH, NHLBI, NIDDK, NIEHS

12) Departmental and University Committees:

Medical Internship Selection Committee, Brigham and Women's Hospital, Boston, MA, 1978-1981.

Committee for Free Medical Care, Brigham and Women's Hospital, Boston, MA, 1979-1980.

Inventory Control Committee, Cardiac Cath Lab, Brigham and Women's Hospital, Boston, MA, 1989-1990.

Standing Committee on Minority Recruitment, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, 1989-1994.

Member, Medical Executive Committee, Mount Sinai Medical Center, Miami, Florida, 1993-Present

Member, Medical Education Committee, Mount Sinai Medical Center, Miami, Florida, 1993-Present

Member, Research Committee, Mount Sinai Medical Center Miami, Florida 1993-Present

Chairman, Credentials Committee, Mount Sinai Medical Center 1997-Present

Member, Mount Sinai Medical Center Institutional Review Board 1999-Present

13) Teaching Experience and Responsibilities:

Teaching Responsibilities:

2009-2013: Program Director of the Mount Sinai Medical Center Cardiology Training Program, Dr. Lamas has: 1] developed a core curriculum according to Accreditation Council for Graduate Medical Education recommendations; 2] developed a clinical research program involving all the fellows; 3] developed a lecture series that covers the Core Curriculum; and 4] is active in bedside teaching and lecturing to the Cardiology fellows and medical residents.

14) Other professional activities:

a) Editorial:

Manuscript reviewer: American Heart Journal; New England Journal of Medicine; PACE; American Journal of Cardiology Associate Editor-Journal of Interventional Cardiac Electrophysiology, Electrophysiology Reviews

Member Editorial Board-American Heart Journal Member of the Advisory Committee: Timely Topics in Medicine, Internet Journal. Editorial Board, Revista Espanola de Cardiologia. Editorial Board, Cardiocore.

b) Consultative:

Research Subcommittee of the Government Relations Committee, North American Society of Pacing and Electrophysiology, Newton Upper Falls, MA, 1992-1997.

Fellowship Committee, North American Society of Pacing and Electrophysiology, Newton Upper Falls, MA, 1992-1994

International Society for Adult Congenital Cardiac Disease.
Executive Committee Member 1995-1998

Councilor of the Florida Chapter American College of Cardiology
District 9. 1996-1999

Clinical Trials Review Committee, National Heart Lung & Blood Institute
Member 1993-1997

American Heart Association Florida Affiliate, Research Peer Review
Committee 1993-1995

Chairman, Special Emphasis Panel, National Heart, Lung, and Blood
Institute 1996

Surgery & Bioengineering Study Section Reviewer, National Heart, Lung,
and Blood Institute 1996

DUCCS Steering Committee Member, Duke University Cooperative
Cardiovascular Studies 1996-2000

Chairman, Clinical Trials Review Committee, National Heart, Lung and
Blood Institute 1997-1998

Consultant, National Heart, Lung and Blood Advisory Council, 1997

Chairman, PREVENT DSMB (NHLBI Trial) 1998-2002

Member MESA DSMB (NHLBI Trial) 1999-2002

Member CREST DSMB (NHLBI Trial) 2005-2010

Board Member of the American Heart Association (Greater Miami
Chapter) 1998-2002

President of the South Florida American Heart Association 2000-2001

Charter Member National Hispanic Advisory Board Pfizer US
Pharmaceuticals 1999-2001

Consultant on dronedarone, Sanofi Aventis, 2009-2010

Medical Monitor, Guided Delivery Systems, 2008-2012

Chairman, RAID DSMB (NHLBI Trial) 2010-2017

Member, ISCHEMIA DSMB (NHLBI Trial) 2011- 2018

15) Publications

A. Original, Peer Reviewed Articles

1. Goldman L, Weinberg M, Weisberg M, Olshen R, Cook E, Sargent R, Lamas G, Dennis C, Wilson C, Decklebaum L, Fineberg H, Stiratelli R, Medical House Staff at Yale-New Haven Hospital and Brigham and Women's Hospital. A computer derived protocol to aid in the diagnosis of emergency room patients with acute chest pain. *New Engl J Med* 1982;307:588-596.
2. Shook T, Kirshenbaum J, Hundley R, Shorey J, Lamas G. Ethanol intoxication complicating intravenous nitroglycerine therapy. *Ann Int Med* 1984;101:498-499.
3. Lamas G, Antman E. Pacemaker mediated tachycardia initiated by coincident P-wave undersensing and ventricular blanking period. *PACE* 1985;8:436-439.
4. Lamas G, Rebecca G, Braunwald N, Antman E. Pacemaker malfunction after nitrous oxide anesthesia. *Am J Cardiol* 1985;56: 995-996.
5. Lamas G, Pfeffer M. Increased left ventricular volumes after myocardial infarction in man. *Am Heart J* 1986;111:30-35.
6. Lamas GA, Muller JE, Turi ZG, Stone PH, Rutherford JD, Jaffe AS, Raabe DS, Rude RE, Mark DB, Califf RM, Gold HK, Robertson T, Passamani ER, Braunwald E and the MILIS Study Group. A simplified method to predict the occurrence of complete heart block during acute myocardial infarction. *Am J Cardiol* 1986; 57:1213-1219.
7. Lamas GA, Mudge GH, Collins JJ, Koster J, Cohn LH, Flatley M, Shemin RJ, Cook EF, Goldman L. Clinical response to coronary artery reoperations. *J Am Coll Cardiol* 1986;8:274-279.
8. Lamas GA, Vaughan D, Pfeffer M. Left ventricular thrombus formation following first anterior wall acute myocardial infarction. *Am J Cardiol* 1988;62:31-35.

9. Lamas G, Dawley D, Splaine K, Folland E, Friedman P, Antman E. Documented symptomatic bradycardia and symptom relief in patients receiving permanent pacemakers: A retrospective analysis of the joint ACC/AHA pacing guidelines. *PACE* 1988; 11:1098-1104.
10. Pfeffer M, Lamas G, Vaughan D, Parisi A, Braunwald E. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. *New Engl J Med* 1988; 319:80-86.
11. Lamas GA, Fish RD, Braunwald NS. Fluoroscopic technique of subclavian venous puncture for permanent pacing: A safer and easier approach. *PACE* 1988;11:1398-1401.
12. Nesto RW, Lamas GA, Barry J. Paradoxical elevation of angina threshold by cold pressor test. *Am J Cardiol* 1989;63: 656-659.
13. Lamas G, Vaughan D, Parisi AF, Pfeffer MA. Effects of left ventricular shape and captopril therapy on exercise capacity after anterior wall acute myocardial infarction. *Am J Cardiol* 1989;63:1167-1173.
14. Lamas GA, Vaughan DE, Pfeffer MA. Significance of a lateral Q wave following first anterior wall acute myocardial infarction. *Am J Cardiol* 1990;65:674-675.
15. Vaughan DE, Lamas GA, Pfeffer MA. Role of left ventricular dysfunction in selective neurohumoral activation in the recovery phase of anterior wall acute myocardial infarction. *Am J Cardiol* 1990;66:529-532.
16. Lamas GA, Keefe JM. The effects of equitation (horseback riding) on a motion responsive DDDR pacemaker. *PACE* 1990; 13:1371-1373.
17. Hoeschen RJ, Reimold SC, Lee RT, Plappert TJ, Lamas GA. The effect of posture on the response to atrioventricular synchronous pacing in patients with underlying cardiovascular disease. *PACE* 1991;14:756-759.
18. Pfeffer MA, Moye LA, Braunwald E, Basta L, Brown EJ, Cuddy TE, Dagenais GR, Flaker GC, Geltmen EM, Gersh BJ, Goldman S, Lamas GA, Packer M, Rouleau JL, Rutherford JD, Steingart RM, Wertheimer JH, for the SAVE Investigators. Selection bias in the use of thrombolytic therapy in acute myocardial infarction. *J Am Coll Cardiol* 1991; 266:528-532.
19. Rouleau JL, Moye LA, de Champlain J, Klein M, Bichet D, Packer M, Dagenais G, Sussex B, Arnold JM, Sestier F, Parker JO, McEwan MMP, Bernstein V, Cuddy TE, Delage F, Nadeau C, Lamas GA, Gottlieb SS, McCans J, Pfeffer MA. Activation of neurohumoral systems following acute myocardial infarction. *Am J Cardiol* 1991;68:80D-86D.
20. Tsevat J, Goldman L, Lamas GA, Pfeffer MA, Chapin CC, Connors KF, Lee TH. Functional status vs. utilities in survivors of myocardial infarction. *Medical Care* 1991;29:1153-1159.

21. Lamas GA, Vaughan DE, Pfeffer MA. Predictors of the development of signs and symptoms of heart failure following first anterior wall acute myocardial infarction. *Cardiovascular Risk Factors* 1991;1(4):522-526.
22. Mitchell GF, Lamas GA, Vaughan DE, Pfeffer MA. Left ventricular remodeling in the year after anterior myocardial infarction: a quantitative analysis of contractile segment lengths and ventricular shape. *J Am Coll Cardiol* 1992;19(6):1136-1144.
23. Lamas GA, Pfeffer MA, Hamm P, Wertheimer J, Rouleau J-L, Braunwald E, for the SAVE Investigators. Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? *N Engl J Med* 1992;327:241-247.
24. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Cuddy TE, Davis BR, Geltman E, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau JR, Rouleau JL, Rutherford J, Wertheimer JH, Morton C. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. *N Engl J of Med* 1992; 327:669-677
25. Strickberger SA, Fish RD, Lamas GA, Cantillon C, Bhatia S, McGowan N, Antman EM, Friedman PL. Comparison of the effects of propranolol versus pindolol on sinus rate and pacing frequency in sick sinus syndrome. *Am J Cardiol* 1993;71:53-56.
26. Rouleau JL, Moye LA, Pfeffer MA, Arnold JM, Bernstein V, Cuddy TE, Dagenais GR, Geltman EM, Goldman S, Gordon D, Hamm P, Klein M, Lamas GA, McCans J, McEwan P, Menapace FJ, Parker JO, Sestier F, Sussex B, Braunwald E. A comparison of management patterns after acute myocardial infarction in Canada and the United States. *N Engl J Med* 1993;328:779-784.
27. Tsevat J, Goldman L, Soukup JR, Lamas GA, Connors KF, Chapin CC, Lee TH. Stability of time-tradeoff utilities in survivors of myocardial infarction. *Med Decision Making* 1993; 13:161-165.
28. Rouleau, JL, Champlain J, Klein M, Bichet D, Moye, L, Packer, M, Dagenais G, Sussex B, Arnold J, Sestier F, Parker J, McEwan P, Bernstein V, Cuddy E, Lamas GA, Gottlieb S, McCans J, Nadeau C, Delage F, Hamm P. Activation of neurohumoral systems in postinfarction left ventricular dysfunction. *J Am Coll Cardiol* 1993; 22:390-8.
29. St. John Sutton, M Pfeffer MA, Plappert T, Rouleau J-L, Moyé LA, Dagenais GR, Lamas GA, Klein M, Sussex B, Goldman S, Menapace, FJ, Parker JO, Lewis S, Sestier F, Gordon DF, McEwan P, Bernstein V, Braunwald E. For the SAVE Investigators. Quantitative two dimensional echocardiographic measurements are major predictors of adverse cardiovascular events following acute myocardial infarction: The protective effects of captopril. *Circulation* 1994; 89 :(1) 68-75.
30. Hall C, Rouleau JL, Moyé L, deChamplain J, Bichet D, Klein M, Sussex B, Packer M, Rouleau J, Arnold MO, Lamas GA, Sestier F, Gottlieb S, Wun, CC, Pfeffer MA. N-Terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction. *Circulation* 1994; 89:1934-1942.

31. Rouleau JL, Packer M, Moyè L, de Champlain J, Bichet D, Klein M, Rouleau JR, Sussex B, Arnold M, Sestier F, Parker JO, McEwan P, Bernstein V, Cuddy E, Lamas GA, Gottlieb SS, McCans J, Nadeau C, Delage F, Wun CC, Pfeffer MA. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: Effect of captopril. *J Am Coll Cardiol* 1994;24:583-591.
32. Rutherford JD, Pfeffer MA, Moyè L, Davis BR, Flaker GC, Kowey PR, Lamas GA, Miller HS, Packer M, Rouleau JL, Braunwald E, on behalf of the SAVE Investigators. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. *Circulation* 1994; 90:1731-1738.
33. Lamas GA, Pashos CL, Normand SLT, McNeil B. Permanent pacemaker selection and subsequent survival in elderly Medicare pacemaker recipients. *Circulation* 1995; 91:1063-1069.
34. Lamas GA, Flaker GC, Mitchell G, Smith SC, Gersh BJ, Wun CC, Moyé L, Rouleau JL, Rutherford JD, Pfeffer MA, Braunwald E, for the Survival and Ventricular Enlargement Investigators. The effect of infarct artery patency on prognosis following acute myocardial infarction. *Circulation* 1995;92:1101-1109.
35. Tsevat J, Duke D, Goldman L, Pfeffer MA, Lamas GA, Soukup JR, Kuntz KM, Lee TH. Cost-Effectiveness of captopril therapy after myocardial infarction. *J Am Coll Cardiol* 1995; 26:914-919.
36. Hartley HL, Flaker GC, Basta L, Menapace F, Goldman S, Davis B, Hamm P, Lamas GA, Moyé L, Wun C, Pfeffer MA. Physical working capacity after acute myocardial infarction in patients with low ejection fraction and effect of captopril. *Am J Cardiol* 1995; 76:857- 860.
37. Reimold SC, Lamas GA, Cantillon CO, Antman EM. Risk factors for the development of recurrent atrial fibrillation: Role of pacing and clinical variables. *Am Heart J* 1995; 129:1127-1132.
38. Loh E, St. John Sutton M, Wun CC, Rouleau JL, Flaker GC, Gottlieb SS, Lamas GA, Moyé L, Goldhaber SZ, Pfeffer MA. Ventricular dysfunction and the risk of stroke after myocardial infarction. *N Engl J Med* 1997;336:251.
39. Lamas GA, Mitchell G, Flaker GC, Smith SC, Gersh BJ, Basta L, Moyé L, Braunwald E, Pfeffer MA. The clinical significance of mitral regurgitation following acute myocardial infarction. *Circulation* 1997;96:827-833.
40. Lamas GA. Pacemaker mode selection and survival: a plea to apply the principles of evidence-based medicine to cardiac pacing practice. *Heart* 1997;78:218-220.
41. St. John Sutton M, Pfeffer MA, Moyé L, Plappert T, Rouleau JL, Lamas GA, Rouleau J, Parker JO, Arnold MO, Sussex B, Braunwald E. Cardiovascular death and left ventricular remodeling two years after myocardial infarction. Baseline predictors and impact of long term use of captopril: Information from the Survival and Ventricular Enlargement (SAVE) Trial. *Circulation* 1997; 96:3294-3299.

42. Lamas GA, Orav J, Stambler B, Ellenbogen KA, Sgarbossa EB, Huang SSK, Marinchak RA, Estes NM, Mitchell GA, Lieberman EH, Mangione CM, Goldman L. Quality of life and clinical events in elderly patients randomized to ventricular versus dual chamber pacing. *N Engl J Med* 1998; 338:1097-1104.
43. Hager WD, Davis BR, Riba A, Moya LA, Wun CC, Rouleau JL, Lamas GA, Pfeffer MA. Absence of a deleterious effect of calcium channel blockers in patients with left ventricular dysfunction following myocardial infarction: The SAVE study experience. *Am Heart J* 1998;135:406-413.
44. Paniagua D, Aldrich HR, Lieberman EH, Lamas GA, Agatston AS. Increased prevalence of significant tricuspid regurgitation in patients with transvenous pacemakers leads. *Am J Cardiol* 1998; 82:1131-1132.
45. Ureña PE, Lamas GA, Mitchell G, Flaker GC, Smith SC, Wackers FJ, McEwan P, Pfeffer MA. Ejection fraction by radionuclide ventriculography and contrast left ventriculogram: A tale of two techniques. *J Am Coll Cardiol* 1999; 33:180-185.
46. Ellenbogen KA, Stambler BS, Orav J, Sgarbossa EB, Tullo NG, Love CA, Wood MA, Goldman L, Lamas GA. Clinical characteristics of patients intolerant to VVIR pacing. *Am J Cardiol* 2000; 86:59-63.
47. Lamas GA, Lee K, Sweeney M, Leon A, Yee R, Ellenbogen K, Greer S, Wilber D, Silverman R, Marinchak R, Bernstein R, Mittelman R, Lieberman EH, Sullivan C, Zorn L, Flaker G, Schron E, Orav J, Goldman L. Design, Rationale, and baseline patient characteristics of the Mode Selection Trial (MOST) in sinus node dysfunction. *Am Heart J* 2000; 140(4):541-551.
48. Doblas JJ, Schor J, Traad E, Carrillo R, Williams D, Lamas GA. Ventricular geometry and operative mortality in patients undergoing mitral valve replacement. *Clinical Cardiology* 2001;24:717-722.
49. Santo-Tomas M, Lopez-Jimenez F, Aldrich HR, Lieberman EH, Lamas GA. Cigar smoking impairs endothelium-dependent brachial artery dilation in healthy young adults. *Am Heart J* 2002; 143:83-86.
50. Paniagua D, Lopez Jimenez F, Londono J, Mangione CM, Fleischmann K, Lamas GA. Outcome and cost-effectiveness of cardiopulmonary resuscitation after in-hospital cardiac arrest in octogenarians. *Cardiology Int. J Cardio Medicine*. 2002;97(1):6-11.
51. Solomon SD, St John Sutton M, Lamas GA, Plappert T, Rouleau JL, Skali H, Moya L, Braunwald E, Pfeffer MA. Ventricular remodeling does not accompany the development of heart failure in diabetic patients after myocardial infarction. *Circulation* 2002; 106:1251-1255.
52. Lamas GA, Lee KL, Sweeney MO, Silverman R, Leon A, Yee R, Marinchak RA, Flaker G, Schron E, Orav J, Hellkamp AS, Goldman L. Ventricular pacing or dual chamber pacing for sinus-node dysfunction. *N Engl J Med* 2002;346:1854-1862.

- 53.Zornoff LAM, Sikali H, Pfeffer MA, St. John Sutton M, Rouleau, JL, Lamas GA, Plappert T, Rouleau JR, Moyé, Lewis SJ, Braunwald E, Solomon SD. Right ventricular dysfunction and risk of heart failure and mortality after myocardial infarction. *J Am Coll Cardiol* 2002;39:1450-1455.
- 54.Lopez-Jimenez F, Goldman L, Orav EJ, Ellenbogen K, Stambler B, Marinchak R, Wilkoff B, Mangione CM, Yoon C, Vitale K, Lamas GA. Health values before and after pacemaker implantation. *Am Heart J* 2002;144.
- 55.Ellenbogen KA, Hellkamp AS, Wilkoff BL, Camunas JL, Love JC, Hadjis TA, Lee KL, Lamas GA. Complications arising after implantation of DDD pacemakers: the MOST experience. *Am J Cardiol.* 2003;92(6):740-741.
- 56.Sweeney MO, Hellkamp AS, Ellenbogen KA, Greenspon AJ, Freeman RA, Lee KL, Lamas GA. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. *Circulation* 2003;107(23):2932-2937.
- 57.Glotzer TV, Hellkamp AS, Zimmerman J. Sweeney MO, Yee R, Marinchak R, Cook J, Paraschos A, Love J, Radoslovich G, Lee KL, Lamas GA, MOST Investigators. Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke report: report of the Atrial Diagnostics Ancillary Study of the Mode Selection Trial (MOST). *Circulation* 2003;107(12):1614-1619.
- 58.Stambler BS, Ellenbogen KA, Orav EJ, Sgarbossa EB, Estes NA, Rizo-Patron C, Kirchhoffer JB, Hadjis TA, Goldman L, Lamas GA; Pacemaker Selection in the Elderly Trial Investigators. Predictors and clinical impact of atrial fibrillation after pacemaker implantation in elderly patients treated with dual chamber versus ventricular pacing. *Pacing Clin Electrophysiol.* 2003 Oct;26(10):2000-2007.
- 59.Flaker G, Greenspon A, Tardiff B, Schron E, Goldman L, Hellkamp A, Lee K, Lamas G; Mode Selection Trial (MOST) Investigators. Death in patients with permanent pacemakers for sick sinus syndrome. *Am Heart J.* 2003 Nov;146(5):887-893.
- 60.Greenspon AJ, Hart RG, Dawson D, Hellkamp AS, Silver M, Flaker GC, Schron E, Goldman L, Lee KL, Lamas GA; MOST Study Investigators. Predictors of stroke in patients paced for sick sinus syndrome. *J Am Coll Cardiol.* 2004 May 5;43(9):1617-1622.
- 61.Sweeney MO, Hellkamp AS, Ellenbogen KA, Glotzer TV, Silverman R, Yee R, Lee KL, Lamas GA; MOST Investigators. Prospective randomized study of mode switching in a clinical trial of pacemaker therapy for sinus node dysfunction. *J Cardiovasc Electrophysiol.* 2004 Feb;15(2):153-160.
- 62.Kenchiah S, Pfeffer MA, St John Sutton M, Plappert T, Rouleau JL, Lamas GA, Sasson Z, Parker JO, Geltman EM, Solomon SD. Effect of antecedent systemic hypertension on subsequent left ventricular dilation after acute myocardial infarction (from the Survival and Ventricular Enlargement trial). *Am J Cardiol.* 2004 Jul 1;94(1):1-8.

- 63.Link MS, Hellkamp AS, Estes NA 3rd, Orav EJ, Ellenbogen KA, Ibrahim B, Greenspon A, Rizo-Patron C, Goldman L, Lee KL, Lamas GA; MOST Study Investigators. High incidence of pacemaker syndrome in patients with sinus node dysfunction treated with ventricular-based pacing in the Mode Selection Trial (MOST). *J Am Coll Cardiol*. 2004 Jun 2;43(11):2066-2071.
- 64.Aguilar D, Skali H, Moya LA, Lewis EF, Gaziano JM, Rutherford JD, Hartley LH, Randall OS, Geltman EM, Lamas GA, Rouleau JL, Pfeffer MA, Solomon SD. Alcohol consumption and prognosis in patients with left ventricular systolic dysfunction after a myocardial infarction. *J Am Coll Cardiol*. 2004 Jun 2;43(11):2015-2021.
- 65.Aude YW, Agatston AS, Lopez-Jimenez F, Lieberman EH, Marie Almon, Hansen M, Rojas G, Lamas GA, Hennekens CH. The national cholesterol education program diet vs a diet lower in carbohydrates and higher in protein and monounsaturated fat: a randomized trial. *Arch Intern Med*. 2004 Oct 25;164(19):2141-2146.
- 66.Davis LL, Vitale KA, Irmiere CA, Hackney TA, Belew KM, Chikowski AM, Sullivan CA, Hellkamp AS, Schron EB, Lamas GA. Body image changes associated with dual-chamber pacemaker insertion in women. *Heart Lung*. 2004 Sep-Oct; 33(5):273-280.
- 67.Kenchiah S, Davis BR, Braunwald E, Rouleau JL, Dagenais GR, Sussex B, Steingart RM, Brown EJ Jr, Lamas GA, Gordon D, Bernstein V, Pfeffer MA; Survival and Ventricular Enlargement Trial. Antecedent hypertension and the effect of captopril on the risk of adverse cardiovascular outcomes after acute myocardial infarction with left ventricular systolic dysfunction: Insights from the Survival and Ventricular Enlargement Trial. *Am Heart J*. 2004 Aug;148(2):356-364.
- 68.Murcia AM, Hennekens CH, Lamas GA, Jimenez-Navarro M, Rouleau JL, Flaker GC, Goldman S, Skali H, Braunwald E, Pfeffer MA. Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction. *Arch Intern Med*. 2004 Nov 8;164(20):2273-2279.
- 69.Nava G, Adams JA, Bassuk J, Wu D, Kurlansky P, Lamas GA. Echocardiographic comparison of cardiopulmonary resuscitation (CPR) using periodic acceleration (pGz) versus chest compression. *Resuscitation*. 2005 Jul; 66(1):91-97.
- 70.Sweeney MO, Hellkamp AS, Lee KL, Lamas GA; Mode Selection Trial (MOST) Investigators. Association of prolonged QRS duration with death in a clinical trial of pacemaker therapy for sinus node dysfunction. *Circulation*. 2005 May 17;111(19):2418-2423. Epub 2005 May 2.
- 71.Shukla HH, Hellkamp AS, James EA, Flaker GC, Lee KL, Sweeney MO, Lamas GA; Mode Selection Trial (MOST) Investigators. Heart failure hospitalization is more common in pacemaker patients with sinus node dysfunction and a prolonged paced QRS duration. *Heart Rhythm*. 2005 Mar;2(3):245-251.
- 72.Rinfret S, Cohen DJ, Lamas GA, Fleischmann KE, Weinstein MC, Orav J, Schron E, Lee KL, Goldman L. Cost-effectiveness of dual-chamber pacing compared with ventricular pacing for sinus node dysfunction. *Circulation*. 2005 Jan 18;111(2):165-172. Epub 2005 Jan 3.

73. Shukla HH, Flaker GC, Hellkamp AS, James EA, Lee KL, Goldman L, Orav EJ, Lamas GA. Clinical and quality of life comparison of accelerometer, piezoelectric crystal, and blended sensors in DDDR-paced patients with sinus node dysfunction in the mode selection trial (MOST). *Pacing Clin Electrophysiol.* 2005 Aug;28(8):762-770.
74. Hochman JS, Lamas GA, Knatterud GL, Buller CE, Dzavik V, Mark DB, Reynolds HR, White HD; Occluded Artery Trial Research Group. Design and methodology of the Occluded Artery Trial (OAT). *Am Heart J.* 2005 Oct;150(4):627-642.
75. Skali H, Zornoff LA, Pfeffer MA, Arnold MO, Lamas GA, Moye LA, Plappert T, Rouleau JL, Sussex BA, St John Sutton M, Braunwald E, Solomon SD; Survival and Ventricular Enlargement (SAVE) Investigators. Prognostic use of echocardiography 1 year after a myocardial infarction. *Am Heart J.* 2005 Oct;150(4):743-749.
76. Lewis EF, Hellkamp AS, Pfeffer MA, Greenspon AJ, Machado C, Singh S, Schron E, Lee KL, Lamas GA. The association of the heart failure score with mortality and heart failure hospitalizations in elderly patients: insights from the Mode Selection Trial (MOST). *Am Heart J.* 2006 Mar;151(3):699-705.
77. Fleischmann KE, Orav EJ, Lamas GA, Mangione CM, Schron E, Lee KL, Goldman L. Pacemaker implantation and quality of life in the Mode Selection Trial (MOST). *Heart Rhythm.* 2006 Jun;3(6):653-659. Epub 2006 Mar 13.
78. Petersen JL, Haque G, Hellkamp AS, Flaker GC, Mark Estes NA 3rd, Marchlinski FE, McAnulty JH, Greenspon AJ, Marinichak RA, Lee KL, Lamas GA, Mahaffey KW; MOST Clinical Events Committee. Comparing classifications of death in the Mode Selection Trial: agreement and disagreement among site investigators and a clinical events committee. *Contemp Clin Trials.* 2006 Jun;27(3):260-268. Epub 2006 Mar 29.
79. Hellkamp AS, Lee KL, Sweeney MO, Link MS, Lamas GA; MOST Investigators. Treatment crossovers did not affect randomized treatment comparisons in the Mode Selection Trial (MOST). *J Am Coll Cardiol.* 2006 Jun 6;47(11):2260-2266. Epub 2006 May 15.
80. Healey JS, Toff WD, Lamas GA, Andersen HR, Thorpe KE, Ellenbogen KA, Lee KL, Skene AM, Schron EB, Skehan JD, Goldman L, Roberts RS, Camm AJ, Yusuf S, Connolly SJ. Cardiovascular outcomes with atrial-based pacing compared with ventricular pacing: meta-analysis of randomized trials, using individual patient data. *Circulation.* 2006 Jul 4;114(1):11-17. Epub 2006 Jun 26.
81. Cubeddu LX, Cubeddu RJ, Heimowitz T, Restrepo B, Lamas GA, Weinberg GB. Comparative lipid-lowering effects of policosanol and atorvastatin: a randomized, parallel, double-blind, placebo-controlled trial. *Am Heart J.* 2006 Nov;152(5):982.e1-5.
82. Hochman JS, Lamas GA, Buller CE, Dzavik V, Reynolds HR, Abramsky SJ, Forman S, Ruzyllo W, Maggioni AP, White H, Sadowski Z, Carvalho AC, Rankin JM, Renkin JP, Steg PG, Mascette AM, Sopko G, Pfisterer ME, Leor J, Fridrich V, Mark DB, Knatterud GL. Coronary Intervention for Persistent Occlusion after Myocardial Infarction. *N Engl J Med.* 2006;355(23):2395-2407. Epub 2006 Nov 14.

83. Dzavik V, Buller CE, Lamas GA, Rankin JM, Mancini GB, Cantor WJ, Carere RJ, Ross JR, Atchison D, Forman S, Thomas B, Buszman P, Vozzi C, Glanz A, Cohen EA, Meciari P, Devlin G, Mascette A, Sopko G, Knatterud GL, Hochman JS. Randomized Trial of Percutaneous Coronary Intervention for Subacute Infarct-Related Coronary Artery Occlusion to Achieve Long-Term Patency and Improve Ventricular Function. The Total Occlusion Study of Canada (TOSCA)-2 Trial. *Circulation* 2006; 114(23):2449-2457. Epub 2006 Nov 14.
84. Lewis EF, Lamas GA, O' Meara E, Granger CB, Dunlap ME, McKelvie RS, Probstfield JL, Young JB, Michelson EL, Halling K, Carlsson J, Olofsson B, McMurray JJ, Yusuf S, Swedberg K, Pfeffer MA; for the CHARM Investigators. Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM. *Eur J Heart Fail* 2007; 9(1):83-91. Epub 2006 Dec 21.
85. Wu D, Bassuk J, Arias J, Kurlansky P, Lozano H, Lamas G, Adams JA. Different roles of nitric oxide synthase isoforms in cardiopulmonary resuscitation in pigs. *Resuscitation*. 2007 Apr; 73(1):144-153. Epub 2007 Feb 21.
86. de Teresa E, Gomez-Doblas JJ, Lamas G; Alzueta J, Fernandez-Lozano J, Cobo E, Navarro X, Navarro-Lopez F, Stockburger M. Preventing ventricular dysfunction in pacemaker patients without advanced heart failure: rationale and design of the PREVENT-HF study. *Europace* 2007 Jun; 9(6):442-446. Epub 2007 Apr 25.
87. Mielniczuk LM, Lamas GA, Flaker GC, Mitchell G, Smith SC, Gersh BJ, Solomon SD, Moya LA, Rouleau JL, Rutherford JD, Pfeffer MA. Left ventricular end-diastolic pressure and risk of subsequent heart failure in patients following an acute myocardial infarction. *Congest Heart Fail*. 2007 Jul-Aug; 13(4):209-214.
88. Lamas GA, Knight JD, Sweeney MO, Mianulli M, Jorapur V, Khalighi K, Cook JR, Silverman R, Rosenthal L, Clapp-Channing N, Lee KL, Mark DB. Impact of Rate Modulated Pacing on Quality of Life and Exercise Capacity - Evidence from the Advanced Elements of Pacing Randomized Controlled Trial (ADEPT). *Heart Rhythm*. 2007 Sep; 4(9):1125-32. Epub 2007 Jun 2
89. Sweeney MO, Bank AJ, Nsah E, Koullick M, Zeng QC, Hettrick T, Sheldon T, Lamas GA. Minimizing ventricular pacing to reduce atrial fibrillation in sinus-node disease. *N Engl J Med*. 2007 Sep 6; 357(10):1000-1008.
90. Adams JA, Wu D, Bassuk J, Arias J, Lozano H, Kurlansky P, Lamas GA. Nitric oxide synthase isoform inhibition before whole body ischemia reperfusion in pigs: Vital or protective? *Resuscitation*. 2007 Sep; 74(3):516-525. Epub 2007 Apr 26.
91. Zagler A, Heimowitz TB, Escolar E, Hussein SJ, Yousef ZR, Steg PG, Vignola PA, Dzavik V, Hochman, Lamas GA. Late intervention on an occluded infarct-related artery: a meta-analysis of the randomized controlled trials. *Clinical Medicine: Cardiology* 2007;1 1-8.

92. Lozano H, Wu D, Bassuk J, Aria J, Kurlansky P, Lamas GA, Adams JA. The effects of prostaglandin inhibition on whole-body ischemia-reperfusion in swine. *Am J Emerg Med.* 2008 Jan; 26(1):45-53.

93. Adams JA, Bassuk JA, Arias J, Wu H, Jorapur V, Lamas GA, Kurlansky P. Periodic acceleration (pGz) CPR in a swine model of asphyxia induced cardiac arrest Short-term hemodynamic comparisons. *Resuscitation.* 2008 Apr; 77(1):132-138. Epub 2007 Dec 31.

94. Bassuk JA, Wu D, Lozano H, Arias J, Kurlansky P, Lamas GA, Adams JA. Non-selective cyclooxygenase inhibition before periodic acceleration (pGz) cardiopulmonary resuscitation (CPR) in a porcine model of ventricular fibrillation. *Resuscitation.* 2008 May; 77(2):250-257. Epub 2008 Jan 31.

95. Sweeney MO, Hellkamp AS, Ellenbogen KA, Lamas GA. Reduced Ejection Fraction, Sudden Cardiac Death, and Heart Failure Death in the Mode Selection Trial (MOST): Implications for Device Selection in Elderly Patients with Sinus Node Disease. *J Cardiovasc Electrophysiol.* 2008 Jun 12. [Epub ahead of print]

96. Adams JA, Bassuk JA, Arias J, Wu H, Jorapur V, Lamas GA, Kurlansky P. Acute Effects of "Delayed Postconditioning" with Periodic Acceleration (pGz) After Asphyxia Induced Shock in Pigs. *Pediatr Res.* 2008 Nov. Epub 2008 Jun 25.

97. Soran OZ, Piña IL, Lamas GA, Kelsey SF, Selzer F, Pilotte J, Lave JR, Feldman AM. A randomized clinical trial of the clinical effects of enhanced heart failure monitoring using a computer-based telephonic monitoring system in older minorities and women. *J Card Fail.* 2008 Nov; 14(9):711-717. Epub 2008 Aug 9.

98. Dzavík V, Steg PG, Barton B, Lamas GA, Hochman JS. A meta-analysis that misses the mark. *J Am Coll Cardiol.* 2008 Aug 12; 52(7):578-580; author reply 580-2.

99. Jorapur V, Steigen TK, Buller CE, Dzavík V, Webb JG, Strauss BH, Yeoh EE, Kurray P, Sokalski L, Machado MC, Kronsberg SS, Lamas GA, Hochman JS, Mancini GB. Distribution and determinants of myocardial perfusion grade following late mechanical recanalization of occluded infarct-related arteries postmyocardial infarction: a report from the occluded artery trial. *Catheter Cardiovasc Interv.* 2008 Nov 15; 72(6):783-9.

100. Mariusz K, Kadziela J, Reynolds HR, Forman SA, Sadowski Z, Barton BA, Mark DB, Maggioni AP, Leor J, Webb JG, Kapeliovich M, Marin-Neto JA, White HD, Lamas GA, Hochman JS. Predictors of Outcome and the Lack of Effect of Percutaneous Coronary Intervention Across the Risk Strata in Patients With Persistent Total Occlusion After Myocardial Infarction: Results from the OAT (Occluded Artery Trial) Study. *J Am Coll Cardiol Intv* 2008 Nov 20; 1; 511-520.

101. Menon V, Pearte CA, Buller CE, Steg PG, Forman SA, White HD, Marino PN, Katritsis DG, Caramori P, Lasevitch R, Loboz-Grudzien K, Zurakowski A, Lamas GA, Hochman JS. Lack of benefit from percutaneous intervention of persistently occluded infarct arteries after the acute phase of myocardial infarction is time independent: insights from Occluded Artery Trial. *Eur Heart J.* 2008 Nov 21. [Epub ahead of print]

102. Rashba EJ, Lamas GA, Couderc JP, Hollist SM, Dzavik V, Ruzyllo W, Fridrich V, Buller CE, Forman SA, Kufera JA, Carvalho AC, Hochman JS; for the OAT-EP Investigators. Electrophysiological Effects of Late Percutaneous Coronary Intervention for Infarct-Related Coronary Artery Occlusion. The Occluded Artery Trial- Electrophysiological Mechanisms (OAT-EP). *Circulation*. 2009 Feb 2. [Epub ahead of print]
103. Mark DB, Pan W, Clapp-Channing NE, Anstrom KJ, Ross JR, Fox RS, Devlin GP, Martin CE, Adlbrecht C, Cowper PA, Ray LD, Cohen EA, Lamas GA, Hochman JS; Occluded Artery Trial Investigators. Quality of life after late invasive therapy for occluded arteries. *N Engl J Med*. 2009 Feb 19; 360(8):774-83.
104. Malek LA, Reynolds HR, Forman SA, Vozzi C, Mancini GB, French JK, Dziarmaga M, Renkin JP, Kochman J, Lamas GA, Hochman JS. Late coronary intervention for totally occluded left anterior descending coronary arteries in stable patients after myocardial infarction: Results from the Occluded Artery Trial (OAT). *Am Heart J*. 2009 Apr; 157(4):724-732.
105. Cantor WJ, Baptista SB, Srinivas VS, Pearte CA, Menon V, Sadowski Z, Ross JR, Meciari P, Nikolsky E, Forman SA, Lamas GA, Hochman JS. Impact of stress testing before percutaneous coronary intervention or medical management on outcomes of patients with persistent total occlusion after myocardial infarction: analysis from the occluded artery trial. *Am Heart J*. 2009 Apr; 157(4):666-672.
106. Dzavik V, Buller CE, Devlin G, Carere RG, Mancini GB, Cantor WJ, Buszman PE, Rankin JM, Vozzi C, Ross JR, Forman S, Barton BA, Lamas AG, Hochman JS. Angiographic and clinical outcomes of drug-eluting versus bare metal stent deployment in the Occluded Artery Trial. *Catheter Cardiovasc Interv*. 2009 May 1; 73(6):771-9.
107. Fleischmann KE, Orav EJ, Lamas GA, Mangione CM, Schron EB, Lee KL, Goldman L; MOST investigators. Atrial fibrillation and quality of life after pacemaker implantation for sick sinus syndrome: data from the Mode Selection Trial (MOST). *Am Heart J*. 2009 Jul; 158(1):78-83.e2.
108. Buller CE, Rankin JM, Carere RG, Buszman PE, Pfisterer ME, Dzavik V, Thomas B, Forman S, Ruzyllo W, Mancini GB, Michalis LK, Abreu PF, Lamas GA, Hochman JS. Percutaneous coronary intervention in the Occluded Artery Trial: Procedural success, hazard, and outcomes over 5 years. *Am Heart J*. 2009 Sep; 158(3):408-415.
109. Lang IM, Forman SA, Maggioni AP, Ruzyllo W, Renkin J, Vozzi C, Steg PG, Hernandez-Garcia JM, Zmudka K, Jimenez-Navarro M, Sopko G, Lamas GA, Hochman JS. Causes of Death in Early MI Survivors With Persistent Infarct Artery Occlusion: Results from the Occluded Artery Trial (OAT). *EuroIntervention*. 2009 Nov; 5(5):610-618.
110. Kruk M, Buller CE, Tchong JE, Dzavik V, Menon V, Mancini GB, Forman SA, Kurray P, Busz-Papiez B, Lamas GA, Hochman JS. Impact of left ventricular ejection fraction on clinical outcomes over five years after infarct-related coronary artery recanalization (from the Occluded Artery Trial [OAT]). *Am J Cardiol*. 2010 Jan 1; 105(1):10-16.

111. Jorapur V, Lamas GA, Sadowski ZP, Reynolds HR, Carvalho AC, Buller CE, Rankin JM, Renkin J, Steg PG, White HD, Vozzi C, Balcells E, Ragosta M, Martin CE, Srinivas VS, Wharton WW, Abramsky S, Mon AC, Kronsberg SS, Hochman JS. Renal impairment and heart failure with preserved ejection fraction early post-myocardial infarction. *World J Cardiol.* 2010 Jan 1; 2(1):13-18.
112. Adams JA, Wu H, Bassuk JA, Arias J, Uryash A, Jorapur V, Lamas GA, Kurlansky P. Periodic acceleration (pGz) prior to whole body ischemia reperfusion injury provides early cardioprotective preconditioning. *Life Sci.* 2010 May 8; 86(19-20):707-715.
113. Steg PG, Kerner A, Mancini GB, Reynolds HR, Carvalho AC, Fridrich V, White HD, Forman SA, Lamas GA, Hochman JS, Buller CE; OAT Investigators Impact of collateral flow to the occluded infarct-related artery on clinical outcomes in patients with recent myocardial infarction: a report from the randomized occluded artery trial. *Circulation.* 2010 Jun 29; 121(25):2724-2730.
114. Shah AM, Pfeffer MA, Hartley LH, Moyé LA, Gersh BJ, Rutherford JD, Lamas GA, Rouleau JL, Braunwald E, Solomon SD. Risk of all-cause mortality, recurrent myocardial infarction, and heart failure hospitalization associated with smoking status following myocardial infarction with left ventricular dysfunction. *Am J Cardiol.* 2010 Oct 1; 106(7):911-6.
115. Soran OZ, Feldman AM, Piña IL, Lamas GA, Kelsey SF, Selzer F, Pilotte J, Lave JR. Cost of medical services in older patients with heart failure: those receiving enhanced monitoring using a computer-based telephonic monitoring system compared with those in usual care: the Heart Failure Home Care trial. *J Card Fail.* 2010 Nov; 16(11):859-66.
116. Steigen TK, Buller CE, Mancini GB, Jorapur V, Cantor WJ, Rankin JM, Thomas B, Webb JG, Kronsberg SS, Atchison DJ, Lamas GA, Hochman JS, Džavík V. Myocardial perfusion grade after late infarct artery recanalization is associated with global and regional left ventricular function at one year: analysis from the Total Occlusion Study of Canada-2. *Circ Cardiovasc Interv.* 2010 Dec; 3(6):549-55
117. Lamelas J, Sarria A, Santana O, Pineda AM, Lamas GA. Outcomes of minimally invasive valve surgery versus median sternotomy in patients age 75 years or greater. *Ann Thorac Surg.* 2011 Jan; 91(1):79-84.
118. Devlin G, Reynolds HR, Mark DB, Rankin JM, Carvalho AC, Vozzi C, Sopko G, Caramori P, Džavík V, Ragosta M, Forman SA, Lamas GA, Hochman JS. Loss of short-term symptomatic benefit in patients with an occluded infarct artery is unrelated to non-protocol revascularization: results from the Occluded Artery Trial (OAT). *Am Heart J.* 2011 Jan; 161(1):84-90.
119. Santana O, Reyna J, Grana R, Buendia M, Lamas GA, Lamelas J. Outcomes of minimally invasive valve surgery versus standard sternotomy in obese patients undergoing isolated valve surgery. *Ann Thorac Surg.* 2011 Feb; 91(2):406-10.
120. Udelson JE, Pearte CA, Kimmelstiel CD, Kruk M, Kufera JA, Forman SA, Teresinska A, Bychowicz B, Marin-Neto JA, Höchtel T, Cohen EA, Caramori P, Busz-

Papiez B, Adlbrecht C, Sadowski ZP, Ruzyllo W, Kinan DJ, Lamas GA, Hochman JS. The Occluded Artery Trial (OAT) Viability Ancillary Study (OAT-NUC): Influence of infarct zone viability on left ventricular remodeling after percutaneous coronary intervention versus optimal medical therapy alone. *Am Heart J.* 2011 Mar; 161(3):611-21.

121. Pineda AM, Santana O, Zamora C, Benjo AM, Lamas GA, Lamelas J. Outcomes of a minimally invasive approach compared with median sternotomy for the excision of benign cardiac masses. *Ann Thorac Surg.* 2011 May; 91(5):1440-4.

122. Stockburger M, Gómez-Doblas JJ, Lamas G, Alzueta J, Fernández-Lozano I, Cobo E, Wiegand U, Concha JF, Navarro X, Navarro-López F, de Teresa E. Preventing ventricular dysfunction in pacemaker patients without advanced heart failure: results from a multicentre international randomized trial (PREVENT-HF). *Eur J Heart Fail.* 2011 Jun; 13(6):633-41.

123. Mihos CG, Santana O, Lamas GA, Lamelas J. Outcomes of right minithoracotomy mitral valve surgery in patients with previous sternotomy. *Ann Thorac Surg.* 2011 Jun; 91(6):1824-7.

124. Le-Bert G, Santana O, Pineda AM, Zamora C, Lamas GA, Lamelas J. The obesity paradox in elderly obese patients undergoing coronary artery bypass surgery. *Interact Cardiovasc Thorac Surg.* 2011 Aug; 13(2):124-7.

125. Deyell MW, Buller CE, Miller LH, Wang TY, Dai D, Lamas GA, Srinivas VS, Hochman JS. Impact of National Clinical Guideline recommendations for revascularization of persistently occluded infarct-related arteries on clinical practice in the United States. *Arch Intern Med.* 2011 Oct 10; 171(18):1636-43.

126. Hochman JS, Reynolds HR, Dzavík V, Buller CE, Ruzyllo W, Sadowski ZP, Maggioni AP, Carvalho AC, Rankin JM, White HD, Goldberg S, Forman SA, Mark DB, Lamas GA; Occluded Artery Trial Investigators. Long-term effects of percutaneous coronary intervention of the totally occluded infarct-related artery in the subacute phase after myocardial infarction. *Circulation.* 2011 Nov 22; 124(21):2320-8.

127. Elkayam LU, Koehler JL, Sheldon TJ, Glotzer TV, Rosenthal LS, Lamas GA. The influence of atrial and ventricular pacing on the incidence of atrial fibrillation: a meta-analysis. *Pacing Clin Electrophysiol.* 2011 Dec; 34(12):1593-9.

128. Astudillo LM, Santana O, Urbandt PA, Benjo AM, Elkayam LU, Nascimento FO, Lamas GA, Lamelas J. Clinical predictors of prosthesis-patient mismatch after aortic valve replacement for aortic stenosis. *Clinics (Sao Paulo).* 2012; 67(1):55-60.

129. Lamas GA, Goertz C, Boineau R, Mark DB, Rozema T, Nahin RL, Drisko JA, Lee KL. Design of the Trial to Assess Chelation Therapy (TACT). *Am Heart J.* 2012 Jan; 163(1):7-12.

130. Skolnick AH, Reynolds HR, White HD, Menon V, Carvalho AC, Maggioni AP, Pearte CA, Gruberg L, Azevedo RE, Schroeder E, Forman SA, Lamas GA, Hochman JS, Džavík V. Comparison of late results of percutaneous coronary intervention among

stable patients ≤ 65 versus > 65 years of age with an occluded infarct related artery (from the Occluded Artery Trial). *Am J Cardiol.* 2012 Mar 1; 109(5):614-9.

131.Reynolds HR, Forman SA, Tamis-Holland JE, Steg PG, Mark DB, Pearte CA, Carvalho AC, Sopko G, Liu L, Lamas GA, Kruk M, Lobo-Grudzien K, Ruzyllo W, Hochman JS. Relationship of female sex to outcomes after myocardial infarction with persistent total occlusion of the infarct artery: analysis of the Occluded Artery Trial (OAT). *Am Heart J.* 2012 Mar; 163(3):462-9.

132.White HD, Reynolds HR, Carvalho AC, Pearte CA, Liu L, Martin CE, Knatterud GL, Džavík V, Kruk M, Steg PG, Cantor WJ, Menon V, Lamas GA, Hochman JS. Reinfarction after percutaneous coronary intervention or medical management using the universal definition in patients with total occlusion after myocardial infarction: Results from long-term follow-up of the Occluded Artery Trial (OAT) cohort. *Am Heart J.* 2012 Apr; 163(4):563-71.

133.Salas MJ, Santana O, Escolar E, Lamas GA. Medical therapy for calcific aortic stenosis. *J Cardiovasc Pharmacol Ther.* 2012 Jun; 17(2):133-8.

134.Freixa X, Džavík V, Forman SA, Rankin JM, Buller CE, Cantor WJ, Ruzyllo W, Reynolds HR, Lamas GA, Hochman JS. Long-term outcomes after a strategy of percutaneous coronary intervention of the infarct-related artery with drug-eluting stents or bare metal stents vs medical therapy alone in the Occluded Artery Trial (OAT). *Am Heart J.* 2012 Jun; 163(6):1011-8. Erratum in: *Am Heart J.* 2013 Apr; 165(4):638.

135.Pineda AM, Santana O, Lamas GA, Lamelas J. Is a minimally invasive approach for re-operative aortic valve replacement superior to standard full resternotomy? *Interact Cardiovasc Thorac Surg.* 2012 Aug;15(2):248-52

136.Santana O, Funk M, Zamora C, Escolar E, Lamas GA, Lamelas J. Staged percutaneous coronary intervention and minimally invasive valve surgery: Results of a hybrid approach to concomitant coronary and valvular disease. *J Thorac Cardiovasc Surg.* 2012 Sep; 144(3):634-9.

137.Santana O, Reyna J, Benjo AM, Lamas GA, Lamelas J. Outcomes of minimally invasive valve surgery in patients with chronic obstructive pulmonary disease. *Eur J Cardiothorac Surg.* 2012 Oct; 42(4):648-52.

138.Hastings RS, Hochman JS, Dzavik V, Lamas GA, Forman SA, Schiele F, Michalis LK, Nikas D, Jaroch J, Reynolds HR. Effect of late revascularization of a totally occluded coronary artery after myocardial infarction on mortality rates in patients with renal impairment. *Am J Cardiol.* 2012 Oct 1; 110(7):954-60.

139.Mihos CG, Santana O, Lamas GA, Lamelas J. Incidence of postoperative atrial fibrillation in patients undergoing minimally invasive versus median sternotomy valve surgery. *J Thorac Cardiovasc Surg.* 2012 Oct 4.

140.Jhaveri RR, Reynolds HR, Katz SD, Jeger R, Zinka E, Forman SA, Lamas GA, Hochman JS. Heart failure in post-mi patients with persistent ira occlusion: prevalence,

risk factors, and the long-term effect of PCI in the Occluded Artery Trial (OAT). *J Card Fail.* 2012 Nov; 18(11):813-21.

141.Nascimento FO, Larrauri-Reyes MC, Santana O, Pérez-Caminero M, Lamas GA. Comparison of Stress Cardiomyopathy in Hispanic and non-Hispanic Patients. *Rev Esp Cardiol.* 2013 Jan; 66(1):67-68. PMID: 23485190

142.Pineda AM, Santana O, Reyna J, Sarria A, Lamas GA, Lamelas J. Outcomes of reoperative aortic valve replacement via right mini-thoracotomy versus median sternotomy. *J Heart Valve Dis.* 2013 Jan; 22(1):50-5. PMID: 23610989

143.Santana O, Reyna J, Pineda AM, Mihos CG, Elkayam LU, Lamas GA, Lamelas J. Outcomes of minimally invasive mitral valve surgery in patients with an ejection fraction of 35% or less. *Innovations (Phila).* 2013 Jan-Feb;8(1):1-5 PMID: 23571786

144.Lamas GA, Goertz C, Boineau R, Mark DB, Rozema T, Nahin RL, Lindblad L, Lewis EF, Drisko J, Lee KL; TACT Investigators. Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial. *JAMA.* 2013 Mar 27; 309(12):1241-50. PMID: 23532240

145.Menon V, Ruzyllo W, Carvalho AC, Almeida de Sousa JM, Forman SA, Jaworska K, Lamas GA, Roik M, Thuairé C, Turgeman Y, Hochman JS. Infarct artery distribution and clinical outcomes in occluded artery trial subjects presenting with non-ST-segment elevation myocardial infarction (from the long-term follow-up of Occluded Artery Trial [OAT]). *Am J Cardiol.* 2013 Apr 1; 111(7):930-5.

146.Overgaard CB, Džavík V, Buller CE, Liu L, Banasiak W, Devlin G, Maggioni AP, Leor J, Burton JR, Reis G, Ruzyllo W, Forman SA, Lamas GA, Hochman JS; for the OAT Investigators. Percutaneous revascularization and long term clinical outcomes of diabetic patients randomized in the Occluded Artery Trial (OAT). *Int J Cardiol.* 2013 Oct 3; 168(3):2416-22. PMID: 23582414

147.Stockburger M, de Teresa E, Lamas G, Desaga M, Koenig C, Habedank D, Cobo E, Navarro X, Wiegand U. Exercise capacity and N-terminal pro-brain natriuretic peptide levels with biventricular vs. right ventricular pacing for atrioventricular block: results from the PREVENT-HF German Substudy. *Europace.* 2014 Jan; 16(1):63-70. PMID: 23861381

148.Lapietra A, Santana O, Mihos CG, Debeer S, Rosen GP, Lamas GA, Lamelas J. Incidence of cerebrovascular accidents in patients undergoing minimally invasive valve surgery. *J Thorac Cardiovasc Surg.* 2013 Sep 26 PMID: 24075464 [Epub ahead of print]

149.Lapietra A, Santana O, Mihos CG, Debeer S, Rosen GP, Lamas GA, Lamelas J. Incidence of cerebrovascular accidents in patients undergoing minimally invasive valve surgery. *J Thorac Cardiovasc Surg.* 2013 Sep 26 PMID: 24075464 [Epub ahead of print]

150. Buendia MA, Santana O, Conde CA, Pineda AM, Zamora C, Lamas GA, Sivina M. Long-term outcome of abdominal aortic aneurysm repair via a retroperitoneal approach. *J Cardiovasc Surg (Torino)*. 2013 Oct 9. PMID: 24104586 [Epub ahead of print]
151. Lamas G, Boineau R, Goertz C, Mark DB, Rosenberg Y, Stylianou M, Rozema T, Nahin RL, Lindblad L, Lewis EF, Drisko JA, Lee KL. Oral High-Dose Multivitamins and Minerals after Myocardial Infarction. A Randomized, Controlled Trial. *Ann Intern Med*. 2013; 159(12): 797-805.
152. Peguero JG, Cornielle V, Gomez SI, Issa OM, Heimowitz TB, Santana O, Goldszer RC, Lamas GA. The Use of Nitrates in the Prevention of Contrast-Induced Nephropathy in Patients Hospitalized After Undergoing Percutaneous Coronary Intervention. *J Cardiovasc Pharmacol Ther*. 2013 Dec 23. PMID: 24367008. [Epub ahead of print]
153. Valdez GD, Mihos CG, Santana O, Heimowitz TB, Goldszer R, Lamas GA, Lamelas J. Incidence of postoperative acute kidney injury in patients with chronic kidney disease undergoing minimally invasive valve surgery. *J Thorac Cardiovasc Surg*. 2013 Dec; 146(6):1488-93. PMID: 23972261
154. Escolar E, Lamas GA, Mark DB, Boineau R, Goertz C, Rosenberg Y, Nahin RL, Ouyang P, Rozema T, Magaziner A, Nahas R, Lewis EF, Lindblad L, Lee KL. The Effect of an EDTA-based Chelation Regimen on Patients With Diabetes Mellitus and Prior Myocardial Infarction in the Trial to Assess Chelation Therapy (TACT). *Circ Cardiovasc Qual Outcomes*. 2014 Jan 1; 7(1):15-24 PMID: 24254885
155. Mihos CG, Santana O, Pineda AM, Lamas GA, Lamelas J. Right anterior minithoracotomy versus median sternotomy surgery for native mitral valve infective endocarditis. *J Heart Valve Dis*. 2014 May; 23(3):343-9. PMID:25296460
156. Lamas Gervasio A., Boineau Robin, Goertz Christine, Mark, Daniel B., Rosenberg Yves, Stylianou Mario, Rozema Theodore, Nahin Richard L., Terry, Chappell L, Lindblad Lauren, Lewis Eldrin F., Drisko Jeanne, Lee Kerry L., EDTA Chelation Therapy Alone and in Combination with Oral High-Dose Multivitamins and Minerals for Coronary Disease: The Factorial Group Results of the Trial to Assess Chelation Therapy, *Am Heart J*. 2014 Jul; 168(1):37-44.e5. PMID: 24952858.
157. Avila MD, Escolar E, Lamas GA. Chelation Therapy after the Trial to Assess Chelation Therapy (TACT): results of a unique trial. *Curr Opin Cardiol*. 2014 Sep; 29(5):481-8. PMID: 25023079.
158. Mark DB, Anstrom KJ, Clapp-Channing NE, Knight JD, Boineau R, Goertz C, Rozema TC, Liu DM, Nahin RL, Rosenberg Y, Drisko J, Lee KL, Lamas GA; Tact Investigators; Quality-of-Life Outcomes With a Disodium EDTA Chelation Regimen for Coronary Disease: Results From the Trial to Assess Chelation Therapy Randomized Trial. *Circ Cardiovasc Qual Outcomes*. 2014 Jul; 7(4):508-16. PMID: 24987051.
159. Adlbrecht C, Huber K, Reynolds HR, Carvalho AC, Dzavik V, Step PG, Liu L, Marino P, Pearte CA, Rankin JM, White HD, Lamas GA, Hochman JS. Effects of timing, location and definition of reinfarction on mortality in patients with totally occluded infarct

released arteries late after myocardial infarction; *Int J Cardiol.* 2014 Jun 1; 174(1):90-5. PMID: 24726166.

160.Santana O, Pineda AM, Cortes-Bergoderi M, Mihos CG, Beohar N, Lamas GA, Lamelas J. Hybrid approach of percutaneous coronary intervention followed by minimally invasive valve operations. *Ann Thorac Surg.* 2014 Jun; PMID: 24725838

161. Peguero JG, Arenas I, Lamas GA; Chelation therapy and cardiovascular disease: Connecting scientific silos to benefit cardiac patients; *Trends Cardiovasc Med.* 2014 Aug; 24. PMID: 25106084

162. Holmqvist F1, Hellkamp AS, Lee KL, Lamas GA, Daubert JP; Adverse Effects of First-Degree AV-Block in Patients with Sinus Node Dysfunction: Data from the Mode Selection Trial. *Pacing Clin Electrophysiol.* 2014 Sep. PMID: 24797760

163.Peguero JG, Issa O, Podesta C, Elmahdy HM, Santana O, Lamas GA. Usefulness of the CHA2DS2VASc score to predict postoperative stroke in patients having cardiac surgery independent of atrial fibrillation. *Am J Cardiol.* 2015 Mar 15; 115(6):758-62. doi: 10.1016/j.amjcard.2014.12.037. Epub 2015 Jan 6.

164.Glotzer TV, Hellkamp AS, Lee KL, Lamas GA. CHA2DS2-VASC and CHADS2 Scores Predict Adverse Clinical Events in Patients with Pacemakers and Sinus Node Dysfunction Independent of Atrial Fibrillation. *Can J Cardiol.* 2015 Aug; 31(8):1004-11. doi: 10.1016/j.cjca.2015.02.020. Epub 2015 Feb 20.

165.Goertz CM, Salsbury SA, Vining RD, Long CR, Pohlman KA, Weeks WB, Lamas GA. Effect of Spinal Manipulation of Upper Cervical Vertebrae on Blood Pressure: Results of a Pilot Sham-Controlled Trial. *J Manipulative Physiol Ther.* 2016 Jun; 39(5):369-380.

166.Arenas IA, Ergui I, Navas-Ancient, Lamas GA. Enhanced vasculotoxic metal excretion in post-myocardial infarction patients following a single edetate disodium-based infusion. *Environ Res.* 2017 Jul 6; 158:443-449.

167.Issa OM, Roberts R, Mark DB, Boineau R, Goertz C, Rosenberg Y, Lewis EF, Guarneri E, Drisko J, Magaziner A, Lee KL, Lamas GA. Effect of high-dose oral multivitamins and minerals in participants not treated with statins in the randomized Trial to Assess Chelation Therapy (TACT). *Am Heart J.* 2018 Jan; 195:70-77.

168.Ujueta F, Arenas IA, Diaz D, Yates T, Beasley R, Navas-Acien A, Lamas GA. Cadmium level and severity of peripheral artery disease in patients with coronary artery disease. *Eur J Prev Cardiol.* 2018 Aug 28:2047487318796585.

169.Ujueta F. Arenas IA, Escolar E, Diaz D, Boineau R, Mark DB, Golden P, Lindblad L, Kim H, Lee KL, Lamas GA. The effect of EDTA-based chelation on patients with diabetes and peripheral artery disease in the Trail to Assess Chelation Therapy (TACT). *J Diabetes Complications.* 2019 April 14.

170. Porudominsky R, Ujueta F, Olivieri B, Beasley R, Lamas GA. Does edetate disodium reduce cost of care of patients with diabetes and critical limb ischemia? *Journal of Vascular and Invasive Radiology*. December 2019. [Abstract]

171. Arenas IA, Ujueta F, Diaz D, Yates T, Olivieri B, Beasley R, Lamas GA. Limb preservation using edetate disodium-based chelation in patients with diabetes and critical limb ischemia: an open label study. *Cureus*. 2019; 11(12):e6477. DOI: 10.7759/cureus.6477

172. Alam ZH, Ujueta F, Arenas IA, Nigra AE, Navas-Acien A, Lamas GA. Urinary Metal Levels after Repeated Edetate Disodium Infusions: Preliminary Findings. *Int J Environ Res Public Health*. 2020; 17(13):4684.

173. Escolar E, Ujueta F, Kim H, Mark DB, Boineau R, Nahin RL, Goertz C, Lee KL, Anstrom KJ, Lamas GA. Possible differential benefits of edetate disodium in post-myocardial infarction patients with diabetes treated with different hypoglycemic strategies in the Trial to Assess Chelation Therapy (TACT). *J Diabetes Complications*. 2020; 34(8):107616. doi: 10.1016/j.jdiacomp.2020.107616.

174. Lewis EF, Ujueta F, Lamas GA, Roberts RS, Mark DB, Nahin RL, Goertz C, Stylianou M, Lee KL. Differential outcomes with edetate disodium-based treatment among stable post anterior vs. non-anterior myocardial infarction patients. *Cardiovasc Revasc Med*. 2020; S1553-8389(20)30179-2. doi: 10.1016/j.carrev.2020.04.005.

175. Porudominski R, Ujueta F, Arenas IA, Lamas GA. Preliminary Cost Estimates of Edetate Disodium Infusions for Critical Limb Ischemia in Patients with Diabetes Mellitus. *Vascular Disease Management*. 2020; 17(7):E137-141.

B. Case Reports

1. Lamas G, Koller L, Antman E, Smith T. Electrocardiogram by Einthoven 63 years earlier. *Am J Cardiol* 1984; 54:1163-1165.

2. Lamas G, Antman E, Gold J, Braunwald N, Collins J. Pacemaker back-up mode reversion and injury during cardiac surgery. *Ann of Thoracic Surg* 1986; 41:155-157.

3. Mahr NC, Valdes A, Lamas GA. Use of glucagon for acute intravenous diltiazem toxicity. *Am J Cardiol* 1997; 79:1570-1571?

4. Benjo AM, Pineda AM, Nascimento FO, Zamora C, Lamas GA, Escolar E. Left main coronary artery acute thrombosis related to energy drink intake. *Circulation*. 2012 Mar 20; 125(11):1447-8.

5. Ujueta F, Arenas I, Yates T, Beasley R, Diaz D, Lamas, GA. Edetate Disodium-Based Treatment in a Patient With Diabetes and Critical Limb Ischemia After Unsuccessful Peripheral Arterial Revascularizations: A Case Report. *Clin Diabetes*. Online Access only: <https://doi.org/10.2337/cd18-0059>.

6. Ujueta F, Lamas GA. Toxic metal chelation with edetate disodium in a patient with diabetes and critical limb ischemia. *Vascular Disease Management*. 2019; 16(5): E55-E57.

7. Ujueta F, Vozi C, Vozi L, Lamas GA. Edetate disodium-based treatment in a woman with diabetes and critical limb ischemia scheduled for lower extremity amputation. *Cureus*. 2019. doi: 10.7759/cureus.

C. Reviews, Chapters and Editorials

1. Lamas GA, Smith T. Atrioventricular block in acute myocardial infarction. *Lifeline* 1983; 1:1-15.
2. Lamas GA, Muller J. Prediction of complete heart block during myocardial infarction. *Cardiology Board Review* 1986; 4:75-87.
3. Lamas GA, Collins JJ, Cohn LH, Mudge GH, Goldman L. Repeat coronary artery bypass operations. *Cardiology Board Review* 1987; 5:114-120.
4. Pfeffer MA, Lamas GA, Vaughan DE, Parisi AF, Braunwald E. Einfluss von captopril auf die progression der ventrikeldilatation nach vorderwandinfarkt. *Munchener Medizinische Wochenschrift* 1988; 43:751-758.
5. Lamas G. Physiologically responsive pacemakers. *Choices in Cardiol* 1989; 3:255-258.
6. Sagastagoitia Gorostiza JD, Lamas GA. Papel de los vasodilatadores en el tratamiento de la insuficiencia cardíaca crónica, in Iriarte Ezkudia MM, Sagastagoitia Gorostiza JD (eds): Insuficiencia cardiaca cronica, Chapter 8. Barcelona, MCR, 1989, pp. 285-298.
7. Lamas G. Left ventricular dilatation following myocardial infarction: Clinical course and potential for therapy. *Cardiology* 1989; 76:112-121.
8. Lamas GA. Physiological consequences of normal atrioventricular conduction: Applicability to modern cardiac pacing. *J Cardiac Surg* 1989; 4:89-98.
9. Lamas GA. Angiotensin-converting enzyme inhibitor therapy in postmyocardial infarction patients, with a focus on cardiac remodeling and cost effectiveness. *Clin Cardiol* 1997; 20: 24-30.
10. Lamas GA. Reduction of post-MI left-ventricular dilatation with captopril. *J Myocardial Ischemia* 1990; 2(6):41-51.
11. Lamas GA, Pfeffer MA. Left ventricular remodeling following acute myocardial infarction: Clinical course and beneficial effects of angiotensin-converting enzyme inhibition. *Am Heart J* 1991; 121(4):1194-1202.
12. Lamas GA, Pfeffer MA, Braunwald E. Patency of the infarct related coronary artery and ventricular geometry. *Am J Cardiol* 1991; 68:41D-51D.

13. Lamas GA. Left ventricular remodeling following myocardial infarction in Cortina A (ed): Congestive Heart Failure: Pathophysiological Bases and Therapeutic Implications. Oviedo, Spain, Prous Science Publishers, 1992, pp. 103-113.
14. Lamas GA, Estes NM, III, Schneller S, Flaker GC. Does dual chamber or atrial pacing prevent atrial fibrillation? The need for a randomized controlled trial. PACE 1992; 15:1109-1113.
15. Lamas, GA. Left ventricular hypertrophy in post-myocardial infarction left ventricular remodeling and hypertension; similarities and contrasts. European Heart Journal 1993;14 (Supplement J) 15-21.
16. Pfeffer MA, Pfeffer JM, Lamas GA. The development and prevention of congestive heart failure following myocardial infarction. Circulation 1993; 87(4):120-125.
17. Vaughan DE, Lamas GA, Pfeffer MA. Left ventricular remodeling in Barnett D, Poulter H, and Francis GS (eds): Congestive Heart Failure: Newer Therapeutics. New York, Marcel Dekker, Publishers 1993 pp.71-90
18. Mitchell G, Pfeffer MA, Lamas G. Ventricular Remodeling After Myocardial Infarction in Sideman S, Beyar R (eds): Advances in experimental medicine and biology. Plenum Publishing Corporation 1993; 346:265-276.
19. Pfeffer MA, Lamas GA. Ventricular Remodeling After Myocardial Infarction: Experimental and Clinical Benefits of ACE inhibition. IN: The Cardiac-Renin-Angiotensin System. Futura Publishing Co.Inc., 1994 Chapter 18, pp.345-358.
20. Taveras JM, Lamas GA. Conceptos actuales en marcapasos. MEDICO Interamericano 1994;11:571-574.
21. Ureña P, Lamas GA. Disfunción ventricular post-infarto del miocardio. Encuentros Cardiológicos 1995; pp.225-235.
22. Connors KF, Lamas GA. Postmyocardial infarction Patients: Experience from the SAVE Trial. Am J of Critical Care 1995; 4:23-28.
23. Prasad R, Lamas GA. Should angiotensin converting enzyme inhibitors be administered to all patients with acute myocardial infarction? European Heart Journal 1995; 16:41-43.
24. Pfeffer MA, Hennekens CH, for the HEART Study Executive Committee from the Division of Cardiology and Preventive Medicine, Harvard Medical School, Brigham & Women's Hospital, Boston, MA. HEART Study Executive Committee: Arnold M, Carberry P, Goldman S, Greaves S, Jugdutt B, Klein M, Lamas GA, Lee Richard, Rapaport E, Rouleau JL, Rutherford J, Stanbrook H, Verrechia D, Warnica W. When A Question Has An Answer: Rationale for Our Early Termination of the HEART Trial. Am J Cardiol. 1995; 75:1173-1175.

25. Saksena S, Epstein AE, Lazzara R, Maloney JD, Zipes DP, Benditt DG, Camm AJ, Domanski MJ, Fisher JD, Gersh BJ, Lamas GA, Lehmann MH, Nickelson DE, Prystowsky EN, Wyse DG. Clinical Investigations of antiarrhythmic devices. Report by the North American Society of Pacing and Electrophysiology, American College of Cardiology, American Heart Association and Working Groups on Arrhythmias and Cardiac Pacing of the European Society of Cardiology. *J Am Coll Cardiol* 1995; 25:961-973.
26. Saksena S, Epstein AE, Lazzara R, Maloney JD, Zipes DP, Benditt DG, Camm AJ, Domanski MJ, Fisher JD, Gersh BJ, Lamas GA, Lehmann MH, Nickelson DE, Prystowsky EN, Wyse G. Clinical investigation of antiarrhythmic devices: A statement for healthcare professionals from a joint task force of the North American Society of Pacing and Electrophysiology, the American Heart Association and the Working Groups on arrhythmias and Cardiac Pacing of the European Society of Cardiology. *PACE* 1995; 18:637-654.
27. Ciccia-MacLean R, Lamas GA. Patency of the infarct-related coronary artery and left ventricular remodelling. IN: Martin G. St. John Sutton. ED. Science Press 1996 Chapter 3, pp.30-46. *Left Ventricular Remodelling After Myocardial Infarction*.
28. Heilbron RG, Lamas GA. Does physiologic pacing improve survival in sinus node dysfunction? An evidence-based approach. ED. Serge Barold and Jacques Mugica. IN: Recent advances in cardiac pacing. Futura Publishing Co. Inc., 1996 Chapter 20 pp.411-432.
29. Crespo F, Lamas GA. Pacemaker selection in the elderly. *Cardiology Board Review* 1996; 13:17-20.
30. Rosado A, Lamas GA. Left ventricular remodeling: clinical significance and therapy. *Basic Res Cardio* 1997; 92:66-68.
31. Lamas GA. Pacemaker mode selection and survival: a plea to apply the principles of evidence-based medicine to cardiac pacing practice. *Heart* 1997; 78:218-220.
32. Lamas GA. Angiotensin-converting enzyme inhibitor therapy in postmyocardial infarction patients, with a focus on cardiac remodeling and cost effectiveness. *Clin Cardiol* 1997; 20: 24-30.
33. Rosado A, Lamas GA; Ed. C.P. Cannon. *Contemporary Cardiology: Management of Acute Coronary Syndromes*. Totowa, NJ. Humana Press, Inc. 1998 Chapter 14. Angiotensin-Converting enzyme inhibitor in acute coronary syndromes.
34. Link MS, Estes, N.A.M., Griffin JJ, Wang PJ, Maloney JD, Kirchhoffer JB, Mitchell GF, Orav J, Goldman L, Lamas GA. *J Int Card Electrophysiology* 1998; 2:175-179.
35. Lopez-Jimenez F, Paniagua D, Lamas GA. The interpretation of negative randomized clinical trials. *Rev Inv Clin* 1998;50:435-440.
36. Doblas JJ, De Teresa E, Lamas GA. Geometría ventricular e insuficiencia cardíaca. *Rev Esp Cardiol* 1999; 52:47-52.

37. Lopez-Jimenez F, Lamas GA. Evidence-Based medicine. Arch Med Res 1999;30:77.
38. Lamas GA. Clinical trials in Cardiac Pacing: Justification, design, and preliminary results of the United States Trials. ED. Panos E. Vardas. IN: Cardiac arrhythmias pacing & electrophysiology. Kluwer Academic Publishers 1999; Chapter 55 pp.399-406.
39. Lopez-Jimenez F., Lamas GA. Metaanalysis: Suma de peras con manzanas o sintesis valida de investigacion clinica. Manual de medicina basada en la evidencia. 1999; Capitulo 13; 143-151.
40. Vassolo HM, Lamas GA. Dual-chamber vs. ventricular pacing in the elderly: quality of life and clinical outcomes. European Heart Journal 1999; 20:1603-1606.
41. Paniagua D, Lamas GA. La necesidad de estudios clinicos para seleccionar el mejor mode de programación del marcapaso. GEMA 1999; 4-7.
42. Griffith KM, Lamas GA. Does mitral regurgitation after MI predict mortality. Cardiology Review 2000;17:11-14.
43. Marroquin O, Lamas GA. Beneficial effects of an open artery on left ventricular remodeling after myocardial infarction. The patent infarct related arteryhypothesis. Prog Cardiovascular Disease 2000;42:4.
44. Lamas GA, Ackermann, A. Clinical evaluation of chelation therapy: Is there any wheat amidst the chaff? Am Heart J. 2000;140:4-5.
45. Eidelman RS, Lamas GA, Hennekens CH, Ridker PM. Aspirin, postmenopausal hormones, and C-reactive protein. Arch Intern Med. 2002 Feb 25;162(4):480-481.
46. Carrillo-Jimenez R, Hennekens CH, Lamas GA. Management of Acute Coronary Syndromes. Totowa, NJ. Humana Press, Inc. 2002.
47. Burkle J, Lamas GA. Post MI LV dysfunction. Book Chapter. Harrison's On-line. 2002.
48. Carrillo-Jimenez R, Lamas GA, Hennekens CH. Plasma levels of brain natriuretic peptide: A potential marker for HIV-related cardiomyopathy. J Cardiovasc Pharmacol Therapeut; 2002.
49. Carrillo-Jimenez R, Treadwell TL, Goldfine H, Buenano A, Lamas GA, Hennekens CH. Brain natriuretic peptide and HIV-related cardiomyopathy. AIDS Read. 2002 Nov;12(11):501-503, 508.
50. Carrillo-Jimenez R, Lamas GA, Hennekens CH. Thiazolidinediones could improve endothelial dysfunction and risk of premature coronary heart disease in HIV-infected patients. J Cardiovasc Pharmacol Ther. 2002 Oct;7(4):207-210.
51. Eidelman RS, Lamas GA, Hennekens CH. The new National Cholesterol Education Program guidelines: clinical challenges for more widespread therapy of lipids to treat and prevent coronary heart disease. Arch Intern Med. 2002 Oct 14;162(18):2033-6.

52. Flaker G, Greenspon A, Tardiff B, Schron E, Goldman L, Hellkamp A, Lee K, Lamas GA. Death in patients with permanent pacemakers for sick sinus syndrome. *Am Heart J* 2003; 146 (5); 887-893.
53. Montanez A, Hennekens CH, Zebede J, Lamas GA. Pacemaker mode selection: the evidence from randomized trials. *Pacing Clin Electrophysiol*. 2003;26(5):1270-82.
54. Lamas GA, Williams A. Have the results of randomized clinical trials of pacing altered the practice of cardiac pacing? *J Cardiovasc Electrophysiol*. 2003 Sep;14(9 Suppl):S15-19.
55. Eidelman RS, Hollar D, Hebert PR, Lamas GA, Hennekens CH. Randomized trials of vitamin E in the treatment and prevention of cardiovascular disease. *Arch Intern Med*. 2004 Jul 26;164(14):1552-1556.
56. Montanez A, Ruskin JN, Hebert PR, Lamas GA, Hennekens CH. Prolonged QTc interval and risks of total and cardiovascular mortality and sudden death in the general population: a review and qualitative overview of the prospective cohort studies. *Arch Intern Med*. 2004 May 10;164(9):943-8. Review. Erratum in: *Arch Intern Med*. 2004 Sep 13;164(16):1796.
57. Azadpour M, Lamas GA. AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction. *Expert Rev Cardiovasc Ther*. 2004 Nov;2(6):891-902. Review.
58. Hussein SJ, Hennekens CH, Lamas GA. An update on clinical trials in pacing: is dual chamber pacing better? *Curr Opin Cardiol*. 2004 Jan;19(1):12-18.
59. Galtes I, Lamas GA. Cardiac Pacing for Bradycardia Support: Evidence-based Approach to Pacemaker Selection and Programming. *Curr Treat Options Cardiovasc Med*. 2004 Oct;6(5):385-395.
60. AC Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr, Alpert JS, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Canadian Cardiovascular Society. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). *Circulation*. 2004 Aug 31;110(9):e82-292.
61. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr, Alpert JS, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK, Ornato JP. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice

Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). *J Am Coll Cardiol*. 2004 Aug 4;44(3):E1-E211.

62. Lamas GA, Ellenbogen KA. Evidence base for pacemaker mode selection: from physiology to randomized trials. *Circulation*. 2004 Feb 3;109(4):443-51. Review.
63. Lozano H, Conde CA, Florin T, Lamas GA. Treatment and prevention of atrial fibrillation with nonantiarrhythmic pharmacologic therapy. *Heart Rhythm*. 2005 Sep;2(9):1000-7. Review.
64. Hussein SJ and Lamas GA. EDTA Chelation Therapy Meets Evidence-Based Medicine. *Br J Cardiol* 2006;13:5-6.
65. Lamas GA, Hussein S. EDTA chelation therapy meets evidence-based medicine. *Complementary Therapies in Clinical Practice* 2006;12; 213-215.
66. Martinez C, Tzur A, Hrachian H, Zebede J, Lamas GA. Pacemakers and defibrillators: recent and ongoing studies that impact the elderly. *Am J Geriatr Cardiol*. 2006 Mar-Apr;15(2):82-87. Review.
67. Lamas GA, Hussein SJ. EDTA chelation therapy meets evidence-based medicine. *Complement Ther Clin Pract*. 2006 Aug;12(3):213-215. Epub 2006 Jul 5.
68. Lamas GA, Hochman JS. Where does the Occluded Artery Trial leave the late open artery hypothesis? *Heart*. 2007 Nov;93(11):1319-1321.
69. Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, Hochman JS, Krumholz HM, Lamas GA, Mullany CJ, Pearle DL, Sloan MA, Smith SC Jr, Anbe DT, Kushner FG, Ornato JP, Pearle DL, Sloan MA, Jacobs AK, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Lytle BW, Nishimura R, Page RL, Riegel B, Tarkington LG, Yancy CW. Canadian Cardiovascular Society; American Academy of Family Physicians; American College of Cardiology; American Heart Association. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2008 Jan 15;51(2):210-247.
70. Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, Hochman JS, Krumholz HM, Lamas GA, Mullany CJ, Pearle DL, Sloan MA, Smith SC Jr; 2004 Writing Committee Members, Anbe DT, Kushner FG, Ornato JP, Jacobs AK, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Lytle BW, Nishimura R, Page RL, Riegel B, Tarkington LG, Yancy CW. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. *Circulation*. 2008 Jan 15;117(2):296-329. Epub 2007 Dec 10.

71. Martinez A, Lamas GA. Resincronización cardíaca. *CardiCore*. 2010. doi:10.1016/j.carcor.2009.12.007.
72. Lamas GA, Escolar E, Faxon DP. Examining Treatment of ST-Elevation Myocardial Infarction: The Importance of Early Intervention. *J Cardiovasc Pharmacol Ther*. 2010 Mar;15(1):6-16.
73. Lamas G. How much atrial fibrillation is too much atrial fibrillation? *N Engl J Med*. 2012 Jan 12;366(2):178-80
74. Lamas GA, Mark D, Lee KL. Chelation Therapy and Cardiovascular Outcomes—In Reply. *JAMA*. 2013;310(4):431-432
75. Solenkova NV, Lamas GA. Should chelation therapy be abandoned? *Clinical Practice*. 2013; 10(5): 551-3.
76. Solenkova NV, Newman JD, Berger JS, Thurston G, Hochman JS, Lamas GA. Metal pollutants and cardiovascular disease: Mechanisms and consequences of exposure. *Am Heart J*. 2014 Dec;168(6):812-822. Epub 2014 Jul 22.
77. Lamas GA. Chelation therapy: a new look at an old treatment for heart disease, particularly in diabetics. *Circulation*. 2015 May 26;131(21):e505-6.
78. Arenas IA, Jacobson J, Lamas GA. Routine use of biventricular pacing is not warranted for patients with heart block. *Circ Arrhythm Electrophysiol*. 2015 Jun;8(3):730-8. doi: 10.1161/CIRCEP.114.000627.
79. Lamas GA, Issa OM. Edetate Disodium-Based Treatment for Secondary Prevention in Post-Myocardial Infarction Patients. *Curr Cardiol Rep*. 2016 Jan;18(2):20.
80. Lamas GA, Ergui I. Chelation therapy to treat atherosclerosis, particularly in diabetes: is it time to reconsider? *Expert Rev Cardiovasc Ther*. 2016 Aug;14(8):927-38.
81. Lamas GA, Navas-Acien A, Mark DB, Lee KL. Heavy Metals, Cardiovascular Disease, and the Unexpected Benefits of Chelation Therapy. *J Am Coll Cardiol*. 2016 May 24;67(20):2411-8.
82. Peguero JG, Lo Presti S, Issa O, Podesta C, Parise H, Layka A, Brenes JC, Lamelas J, Lamas GA. Simplified prediction of postoperative cardiac surgery outcomes with a novel score: R2CHADS2. *Am Heart J*. 2016 Jul;177:153-9.
83. Lamas GA. MY APPROACH to the use of chelation therapy. *Trends Cardiovasc Med*. 2016 Aug;26(6):583-4.
84. Lamas GA, Ergui I. Chelation therapy to treat atherosclerosis, particularly in diabetes: is it time to reconsider? *Expert Rev Cardiovasc Ther*. 2016 Aug;14(8):927-38.

85. Aneni EC, Escolar E, Lamas GA. Chronic Toxic Metal Exposure and Cardiovascular Disease: Mechanisms of Risk and Emerging Role of Chelation Therapy. *Curr Atheroscler Rep*. 2016 Dec;18(12):81.
86. Diaz D, Fonseca V, Aude YW, Lamas GA. Chelation therapy to prevent diabetes-associated cardiovascular events. *Curr Opin Endocrinol Diabetes Obes*. 2018 May 24. doi: 10.1097/MED.0000000000000419.
87. Lamas G. Commentary on: Environmental Toxic Metal Contaminants and Risk of Cardiovascular Disease: Systematic Review and Meta-Analysis. PracticeUpdate website. Available at: <http://www.practiceupdate.com/content/environmental-toxic-metal-contaminants-and-risk-of-cardiovascular-disease/72837/65/2/1>. Accessed September 12, 2018
88. Diaz D, Fonseca V, Aude YW, Lamas GA. Chelation therapy to prevent diabetes-associated cardiovascular events. *Curr Opin Endocrinol Diabetes Obes*. 2019 Aug; 25 (4) 258-266.
89. Alam, ZH, Ujueta F, Lamas GA, Potential role of edetate disodium-based therapy in the treatment of atherosclerosis in patients with diabetes. *Current Research in Diabetes & Obesity Journal*. 2019; 11(3):555811.
90. Calderon Moreno R, Navas-Acien A, Escolar E, Nathan DM, Newman J, Schmedtje JF, Diaz D, Lamas GA, Fonseca V. Potential Role of Metal Chelation to Prevent the Cardiovascular Complications of Diabetes. *J Clin Endocrinol Metab*. 2019 Jul 1;104(7):2931-2941.

D. Patents- N/A

E. Abstracts

1. Lamas G, Pfeffer M. Spectrum of left ventricular volumes in patients with isolated left anterior descending coronary artery disease. *J Am Coll Cardiol* 1984;3:571A.
2. Lamas G, Goldman L, Mudge GH Jr et al. Clinical response to coronary artery surgery. *Clinical Research* 1984;32:226A.
3. Nesto R, Lamas G, Barry J, Braunwald E. Paradoxical elevation of angina threshold by cold pressor test. *Circulation* 1984;70:11452A.
4. Lamas G, Muller J, Turi Z, Stone P, Rude R, Jaffe A, Raabe D, Settergren S, Poole WK, Passamani E, Braunwald E, and the MILIS Study Group. A simplified method to predict the occurrence of complete heart block during myocardial infarction. *Circulation* 1984;70:II-310A
5. Lamas G, Vaughan D, Pfeffer M. Dyskinesia, but not akinesia predicts the presence of left ventricular thrombus in acute anterior myocardial infarction. *J Am Coll Cardiol* 1986;7:148A.

6. Lamas G, Dawley D, Splaine K, Friedman PL, Folland E, Antman E. Does documenting a symptomatic bradycardia increase the likelihood of symptom relief in patients receiving permanent pacemakers? *PACE* 1986;9:280A.
7. Lamas G, Muller J, Turi Z, Mark D, Califf R, Jaffe A, Raabe D, Rude R, Stone P, Rutherford J, Gold H, Passamani E, Braunwald E, and the MILIS Study group. Validation of a simplified method to predict the occurrence of complete heart block in patients with acute myocardial infarction. *PACE* 1986;9:291A.
8. Lamas G, Vaughan D, Hartley H, Pfeffer M. Value of submaximal exercise testing after first anterior infarction in identifying patients with multivessel disease. *J Amer Coll Cardiol* 1987;9:194A.
9. Pfeffer MA, Lamas GA, Vaughan DE, Parisi AF, Braunwald E. Attenuation of progressive ventricular enlargement following anterior myocardial infarction in man by captopril. *Circulation* 1987;76:IV-171A.
10. Lamas G, Pfeffer M, Vaughan D, Parisi A, Braunwald E. Left ventricular contour following anterior MI: An important determinant of exercise capacity in man. *Clin Res* 1988;36:604A.
11. Lamas G, Vaughan D, Parisi AF, Pfeffer MA. LV shape as a predictor of exercise capacity following anterior MI: effects of captopril. *Circulation* 1988;78:IV-1876A.
12. Raby KE, Lamas GA, Vaughan DE, Hartley LH, Pfeffer MA. Value of exercise ST elevation 3 months after anterior myocardial infarction. *Clin Res* 1989;37:286A.
13. Vaughan DE, Lamas GA, Pfeffer MA. Selective neurohumoral activation in the recovery phase of anterior myocardial infarction in man. *J Am Coll Cardiol* 1989;13:92A.
14. Mitchell GF, Lamas GA, Vaughan DE, Pfeffer MA. Infarct expansion does not contribute to late left ventricular enlargement. *Circulation* 1989;80:II-589A.
15. Pfeffer MA, Braunwald E, Cuddy TE, Flaker GC, Gersh BJ, Goldman S, Lamas GA, Moyè LA, Steingart R, Rouleau J, for the SAVE Investigators. Selection bias in the use of thrombolytic therapy in acute myocardial infarction. *Circulation* 1989;80:II-522A.
16. Rouleau J-L, Arnold JM, Bernstein V, Cuddy T, Dagenais G-R, Geltman E, Goldman S, Gordon D, Lamas G, McCans J, McEwan P, Menapace F, Parker J, Pfeffer M, Sestier F, Sussex B for the SAVE Investigators. Post myocardial infarction (MI) management patterns of patients in the Survival and Ventricular Enlargement (SAVE) study at Canadian and US centers. *J Am Coll Cardiol* 1990;15(2):221A.
17. Lamas GA, Pfeffer MA, Hamm P, Jacobson K, Rouleau JL, Wertheimer J, Braunwald E, for the SAVE Investigators. The impact of clinical trials on the practice of cardiology. *Circulation* 1991;84(2):II-367A.
18. St. John Sutton MG, Pfeffer MA, Plappert T, Gordon DF, Lamas GA, Lewis SJ, Menapace FJ, Moye LA, Parker JO, Rouleau JL, Braunwald E. Quantitative 2D

echocardiography is a major prognostic factor for survival following myocardial infarction. *Circulation* 1991;84(2):II-66A.

19. Lamas GA, Pashos C, Normand SL, McNeil B, Mt. Sinai Medical Center and the University of Miami School of Medicine and Harvard Medical School. Natural history of sick sinus syndrome (SSS) following pacemaker implantation. *European Journal of Cardiac Pacing and Electrophysiology* 1994;4:145A
20. Lamas GA, St. John Sutton, MG, Flaker GC, Mitchell GF, Smith SC, Gersh BJ, Pfeffer MA, Braunwald E. Infarct artery patency does not prevent LV remodeling. Abstract presentation ACC 44th Annual Scientific Session 1995. *J Am Coll Cardiol* 1995;104A
21. Libys J, Agatston AS, Glickman S, Lamas GA, Viamonte M, Janowitz WR. The noninvasive documentation of coronary artery remodeling using ultrafast computerized tomography. *J Invest Med* 1995;43:386A.
22. Prashad R, Agatston AS, Lamas GA, Lieberman EH. Multiplane transesophageal echocardiographic assessment of valvular aortic stenosis. *J Invest Med* 1995;43: 386A.
23. Lamas GA, Pashos CL, Normand SL, McNeil BJ. Effect of pacing mode on first hospitalization for atrial fibrillation, stroke, or heart failure in Medicare pacemaker patients. *PACE* 1995; 18:58A.
24. Estes M, Griffin J, Wang PJ, Maloney J, Kirchhoffer J, Mitchell G, Orav J, Goldman L, Lamas GA. Morbidity and mortality of permanent dual chamber pacemaker implantation in the elderly. *PACE* 1995;18:181A.
25. Stambler BS, Lamas GA, Hoffman SW, Sargent DA, Wood MA, Ellenbogen KA. Is atrial refractoriness shorter in VVI than DDD paced patients? *PACE* 1995; 18:351A.
26. Pfeffer MA, LaMotte FS, Arnold M, Rouleau JL, Goldman S, Greaves S, Klein M, Lamas GA, Lee RT, Lindpaintner KC, Menapace FJ, Rapaport E, Ricker PM, Rutherford JD, Solomon SD, Timmis GC, Wayne JW, Hennekens CH. Titration of angiotensin converting enzyme inhibition in acute anterior infarction: The healing and early afterload reducing therapy (HEART) study. *Circulation* 1995;92:1-19A.
27. St. John Sutton M, Pfeffer MA, Moye LA, Rouleau JL, Lamas GA, Arnold JM, Cuddy TE, Sussex BA, Braunwald E. Determinants of left ventricular thrombus post-infarction are extent and location of wall motial abnormality and left ventricular cavity shape. *Circulation* 1995;92:1-91A.
28. Ureña PE, Lamas GA, Mitchell G, Flaker GC, Smith SC, Gersh BJ, Wackers F, McEwen P, Pfeffer MA. Ejection fraction by radionuclide ventriculography vs. Contrast left ventriculogram: A tale of two techniques. *Circulation* 1995;92:1-92A.
29. Lamas GA, Ellenbogen KA, Griffin JJ, Wilkoff BL, Sgarbossa E, Huang S, Marinchak RA, Mitchell G, Estes M, Venditti FJ, Stambler B, Ellenbogen K, Pinsky S, Lieberman EH, Mitchell G, Bush D, Huang S, Henthorn R, Orav J, Lamas GA., for the PASE Investigators, West Roxbury VAMC, West Roxbury MA, and Mount Sinai Medical

- Center, Miami Beach, Florida. Development of post-implant atrial fibrillation(AFIB) during DDDR versus VVIR pacing in the PASE trial. PACE 1996;19:214A.
30. Stambler BS, Lamas GA, Hoffman SW, Sargent DA, Wood MA, Ellenbogen KA., McGuire VAMC, Medical College of Virginia, Richmond, VA. Is atrial refractoriness shorter in VVI than DDD paced patients. PACE 1995;18:351A.
 31. Development of post-implant atrial fibrillation(AFIB) during DDDR versus VVIR pacing in the PASE trial. PACE 1996;19:214A.
 32. Lamas GA, Maloney JD, Rizo-Patron C, Lieberman EH, Mangione C, Orav J, Goldman L. Quality of life and clinical events in DDDR versus VVIR paced patients: Design and preliminary results of a randomized trial. Circulation 1995;92:1-533A.
 33. Lieberman EH, Ureña PE, Orav J, Marinchak RA, Venditti FJ, Zimmerman JP, Lamas GA. Clinical predictors of acute atrial implantation parameters. Circulation 1995;92:1-533A.
 34. St. John Sutton M, Pfeffer MA, Plappert T, Moyé L, Rouleau JL, Lamas GA, Rouleau J, Menapace F, Parker JO, Braunwald E. Echocardiographic estimate of infarct size predicts adverse cardiac events and left ventricular remodeling in survivors of acute myocardial infarction. Circulation 1995;92:1-591A.
 35. Heilbron R, Lamas GA. An evidence based approach to pacing in sinus node dysfunction. EUR J.C.P.E.1996;6:541A.
 36. Lamas GA, Mitchell GF, Flaker GC, Smith SC, Gersh BJ, Geltman EM, Braunwald E, Pfeffer MA. The predictive value of LV systolic sphericity index: A magnification independent assessment of LV shape. J Am Cardiol Coll 1996; 27:223A.
 37. Paniagua D, Aldrich HR, Lieberman EH, Agatston AS, Lamas GA Increased prevalence of significant tricuspid regurgitation in patients with transvenous pacemaker leads. JAm Cardiol Coll 1996;27:236A.
 38. Lamas GA, Stambler B, Mittleman R, Wilkoff B, Keim S, Brinker J, Bernstein R, Hayes J, Greenberg S, Orav J, Goldman L. Clinical events following DDDR versus VVIR Pacing: Results of a prospective trial. PACE 1996;19:(4)619A.
 39. Stambler B, Ellenbogen K, Pinsky S, Lieberman E, Mitchell G, Bush D, Huang S, Henthorn R, Orav J, Lamas GA. Development of post-implant atrial fibrillation (AFIB) during DDDR versus VVIR pacing in the PASE trial. PACE 1996; 19:(4)619A.
 40. Gomez JW, Aldrich HR, Lamas GA, Agatston AS. Effect of age on pulmonary vein flow pattern in a population with normal cardiac structure. J Invest Med 1996;44:291A.
 41. Paniagua D, Aldrich HR, Lamas GA, Lieberman EH, Agatston AS. Association between mitral valve prolapse and other regurgitant valvular lesions in a 37,705 echocardiogram database. J Invest Med 1996;44:290A.

42. Cespedes EM, Aldrich HR, Lamas GA, Agatston AS, Williams DB, Traad EA, Lieberman EH. Effects of aortic valve replacement on the severity of mitral regurgitation. *J Invest Med* 1996;44:209A.
43. Agatston AS, Janowitz WR, Kaplan GS, Lee D, Prashad R, Viamonte M, Lamas GA. Electron beam coronary calcium predicts future coronary events. *Circulation* 1996;8:1-360.A
44. Eguia L, Lamas GA, Hager D, Kowey P, Pfeffer MA, Braunwald E. The long-term significance of early conduction disturbances in MI survivors with LV dysfunction. *PACE* 1997;20:102A.
45. Gutt M, Lopez Jimenez, Garces M, Lamas GA, Schneiderman N. State anxiety but not depression score is associated with plasma fibrinogen level in post MI patients. *Ann Behav Med* 1998;2:3313.
46. Paniagua D, Londono J, Aldrich H, Lopez-Jimenez F, Lamas GA. Outcome of cardiopulmonary resuscitation after in hospital cardiac arrest in octogenarians. *J Am Coll Cardiol* 1998;31:343A.
47. Lopez-Jimenez F, Heilbron R, Almon M, Korn H, Lamas GA, Agatston AS. The beneficial effect of a high-fat high-protein low carbohydrate diet on body weight and HDL cholesterol. *J Am Coll Cardiol* 1998;31:88A.
48. Yoon C, Lopez Jimenez F, Orav J, Stambler B, Ellenbogen K, Goldman L, Lamas GA. Quality of life improvement 3 months following pacemaker implantation in elderly patients. *PACE* 1998;21:748A.
49. Sadanandan S, Lamas G, Buller C, Dzavik V, Terrin M, Steingart R, Mark D, Thompson B, Wagner G, Kopecky S, Wong SC, Hochman J. Angiographic characteristics and management of occluded infarct related artery following acute myocardial infarction- Findings from registry of the open artery trial. *J Am Coll Cardiol* 1999;33:379A.
50. Santo-Tomas M, Lopez-Jimenez F, Aldrich HR, Lamas GA, Lieberman EH. Debunking the Yuppie Habit: Cigars and endothelial function. *J Am Coll Cardiol* 1999;33:233A.
51. Lopez-Jimenez F, Lamas GA, Yoon C, Orav J, Mangione C, Ellenbogen K, Goldman L. Health values before and after pacemaker implantation. *Circulation* 1998;17:63A.
52. Aude YW, Lopez-Jimenez F, Lamas GA, Almon M, Hansen M, Rojas G, Lieberman EH, Russell G, Heilbron R, Agatston AS. Randomized trial comparing a high-fat, low carbohydrate diet to the National Cholesterol Education Program Step II Diet. *J Am Coll Cardiol* 1999;33:297A.
53. Lopez-Jimenez F, Lieberman EH, Yoon C, Griffin J, Olshansky B, Lamas GA. Clinical determinants of atrial and ventricular capture threshold in the RAMP trial. *PACE* 19;22:163A

54. Jimenez-Navarro M, Lamas GA, Lopez-Jimenez F, Pfeffer M, Geltman E, Rutherford J, Gersh B. Long term prognosis following MI in diabetic patients with left ventricular dysfunction. *Circulation* 1999;100:I-377A.
55. Lopez-Jimenez F, Jimenez Navarro M, Lamas GA, Rouleau JL, Pfeffer MA, Hartley H. A high level of physical activity before an acute myocardial infarction improves survival and reduces clinical events after myocardial infarction. *Circulation* 1999;100:I-523A.
56. Lynch JE, Kirchhoffer JB, Cook JR, Kabell G, Orav JE, Lamas GA. Utility of the surface ECG and patient characteristics for prediction of atrial sensing measures during pacemaker implantation. *Circulation* 1999;100:I-569A.
57. Lopez-Jimenez F, King D, Londono JC, Lamas GA, Gaziano M, Solomon S, Agatston AS. Degenerative aortic valve disease as an atherosclerotic process: The correlation between aortic valve calcification and coronary artery calcification. *J Am Coll Cardiol* 2001;37:483A.
58. Alonso R, Eidelman R, King DG, Lamas G, Agatston A. Long-term changes in coronary calcium score as evaluated by electron beam tomography scan. *J Am Coll Cardiol* 2001;37:429A.
59. Aude YW, Lamas GA, Lopez-Jimenez F, Almon M, Hansen M, Lieberman EH, Rojas G, Superko R, Agatston A. Results of a randomized trial comparing a high fat low carbohydrate diet to the NCEP step 2 diet: Effect on LDL cholesterol subclasses. *J Am Coll Cardiol* 2001;37:280A.
60. Zornoff L, Skali H, St. John Sutton M, Rouleau J, Lamas G, Lewis S, Plappert T, Rouleau J, Moye L, Pfeffer M, Solomon S. Right ventricular function is a predictor of outcome in patients with left ventricular dysfunction after myocardial infarction. The Survival and Ventricular Enlargement Trial. *J Am Coll Cardiol* 2001;37:156A.
61. Leon AR, Marinchak R, Yee R, Mittleman R, Tolentino A, Montañez A, Hellkamp A, Lee KL, Lamas GA. Incidence of atrial fibrillation in patients with sinus node dysfunction. *Circulation* 2001;104:1823A.
62. Montañez A, Lamas GA, Zebede J, Geltman E, Flaker G, Rutherford J, Rouleau JL, Hennekens CH, Pfeffer MA. Atrial fibrillation during acute myocardial infarction in patients with left ventricular dysfunction predicts increased long-term mortality. *Circulation* 2001;104:3640A.
63. Link MS, Estes MNA, Ellenbogen KA, Ibrahim BB, Greenspon AJ, Rizo-Patron CA, Goldman L, Hellkamp A, Lee KL, Lamas GA. High incidence of pacemaker syndrome in patients with sinus node dysfunction treated with VVIR pacing in MOST. *Circulation* 2001;104:1824A.
64. Skali H, Zornoff LAM, Pfeffer MA, St. John Sutton MG, Rouleau JL, Lamas GA, Plappert T, Rouleau J, Moye L, Lewis S, Solomon SD. Prognostic value of right ventricular function after the first year following myocardial infarction in patients with left ventricular dysfunction. The survival and ventricular enlargement trial. *Circulation* 2001;104:3556A.

65. Ramirez W, Lamas GA, Vignola P, Mitchell GF, Flaker G, Smith SC, Hennekens CH, Pfeffer MA. Clinical and angiographic predictors of heart failure in patients with left ventricular dysfunction after myocardial infarction. *Circulation* 2001;104:2371A.
66. Flaker G, Greenspon A, Tardiff B, Schron E, Goldman L, Hellkamp A, Lee KL, Lamas GA. Cause of death in elderly patients with pacemakers for sick sinus syndrome. *Circulation* 2001;104:3104A.
67. Montañez A, Tolentino A, Hellkamp AS, Zebede J, Bernstein RC, Wilkoff BL, Lee KL, Lamas GA. Diagnosing atrial fibrillation in a randomized pacemaker trial: need for an ECG Core Lab. *PACE* 2002;24:487A.
68. Davis LL, Vitale KA, Imiere CA, Hackney TA, Belew KM, Chikowski AM, Sullivan CA, Hellkamp A, Schron EB, Lamas GA. Psychosocial Adaptation of patients in a long term pacemaker trial. *PACE* 2002;24:114A.
69. Sweeney MO, Hellkamp AS, Greenspon AJ, Mittleman R, McAnulty J, Ellenbogen K, Freedman R, Lee KL, Lamas GA. Effect of pacing mode and cumulative percent time ventricular paced on heart failure patients with sick sinus syndrome and baseline QRS duration < 120 milliseconds in MOST. *PACE* 2002;24:155A.
70. Sweeney MO, Hellkamp AS, Greenspon AJ, Silverman R, Ibrahim B, Estes M, Marinchak R, Love J, Goldman L, Lee KL, Lamas GA. Baseline QRS duration ≥ 120 milliseconds and cumulative percent time ventricular paced predicts increased risk of heart failure, stroke and death in DDDR-paced patients in sick sinus syndrome in MOST. *PACE* 2002; 24:672A.
71. Lamas GA, Cook J, Varma S, Silver M, Mandrola J, Nsha E, Rizo- Patron C, Knight D, Mark D. The association of chronotropic incompetence with poor quality of life: Conceptual basis of ADEPT. *Europace* 2002;3:41/4A.
72. Greenspon AJ, Flaker MO, Sweeney M, Silver S, Greer F, Ehlert B, Ibrahim B, Zebede J, Conti J, Love J, Kirchhoffer L, Goldman L, Hellkamp A, Lee KL, Lamas GA. DDDR pacing reduces incidence of heart failure when compared to VVIR pacing in sinus node dysfunction. *Europace* 2002;3:112/3A.
73. Lamas GA, Lee K, Sweeney M, Silverman R, Leon A, Yee R, Marinchak R, Flaker G, Schron E, Hellkamp A, Goldman L. Results of a randomized trial of VVIR vs. DDDR pacing in sinus node dysfunction. *Europace* 2002;3:112/4A.
74. Lamas GA, Battle J, Minshall-Liu D, Knight D, Undesser K, Autry G, Lee KL, Mark D. An internet based system of verifying and correcting pacemaker programming in a multicenter randomized trial. *Europace* 2002;3:183PW4A.
75. Lamas GA, Lima V, Fernandes R, Brizolara A, Caramori P, Forman A, Hochman JS. The Occluded Artery Trial (OAT): Baseline Characteristics of 621 Randomized Patients. *Arq Bras Cardiol* 2002; 79, Suppl III: 9.

76. Lamas GA, Caramori P, Lasevitch R, Souza JM, Alves C, Forman S, Hochman J. Total Coronary Occlusion Late after MI in the Occluded Artery Trial (OAT)- What Do Patients Want? Observations from the OAT Registry. *Arq Bras Cardiol* 2002; 79, Suppl III: 35.
77. Vozzi C, Paloantonio, D, Cardona M, Forman S, Lamas G, Hochman J. El Estudio de la Arteria Ocluída (OAT): Características Basales de 621 Pacientes Randomizados. *Revista Argentina de Cardiología* 2002; 70(Suppl 3) 99.
78. Burgos M, Cantón RT, Hernandez JM, Rincón A, Villalta M, Forman S, Lamas G, Hochman J. ESTUDIO OAT (Occluded Artery Trial). Diseño y Características de los Primeros 621 Pacientes Randomizados. *Rev Esp Cardiol* 2002;55(Suppl 2)189.
79. Moccetti T, Ceseri M, Verna E, Vilella M, Forman S, Lamas G, Hochman J, Maggioni A. Modelli Comportamentali Nel Trattamento Dell'infarto Miocardico Acuto: Analisi Su 1835 Pazienti Ospedalizzati Nei Centri Internazionali Partecipanti Allo Studio Oat (Occluded Artery Trial). *Emodinamica* 2002;30(Supl.)15.
80. Dzavik V, Buller CE, Ross JR, Abreu PF, Fridrich V, Martin CE, Slater J, Cohen EA, Rankin J, Renkin J, Burton JR, Verna E, Leor J, Pfisterer M, Menon V, Forman S, Lamas GA, Hochman JS. Patient and Physician Preferences for Therapy of an Occluded Infarct-Related Artery Late After Myocardial Infarction. Observations from the Registry of the Occluded Artery Trial (OAT). *Circulation* 2002;106:1809A.
81. Aguilar D, Skali H, Moye LA, Lamas GA, Rouleau JL, Pfeffer MA, Solomon SD. Moderate Baseline Alcohol Consumption Does Not Increase the Risk of Heart Failure in Post-Myocardial Infarction Patients with Depressed Left Ventricular Function. *Circulation* 2002;106:2533A.
82. Glotzer TV, Hellkamp AS, Zimmerman J, Sweeney M, Yee R, Marinchak R, Cook J, Paraschos A, Love J, Radoslovich G, Lee K, Lamas G. Symptoms Are an Unreliable Predictor of the Presence of Clinically Important Supraventricular Tachycardias: Report of the Atrial Diagnostics Ancillary Study of MOST. *Circulation* 2002;106:2979A.
83. Verna E, Marini M, Moccetti T, Vilella M, Forman S, Lamas GA, Hochman J, Maggioni A. Preferenze Del Medico E Del Paziente Riguardo All'angioplastica Coronarica Tardiva Dopo Infarto Miocardico Dati Del Registro O.A.T. (Occluded Artery Trial). *Ital Heart J* 2002; 3(Suppl 7): 76S.
84. Robledo-Carmona J, Hellkamp A, Montanez A, Tolentino A, Sweeney M, Marinchak R, Zebede J, Conti J, Russo A, Lee K, Lamas G. More Atrial Pacing Reduces the Development of Atrial Fibrillation in Patients with Sick Sinus Syndrome. *Pacing And Clin Electrophysiol* 2003;26. (Abstract)
85. Lewis E, Pfeffer M, Hellkamp A, Greenspon A, Lamas G. The Association of the Heart Failure Score with Mortality and Hospitalizations in Pacemaker Patients. *Journal of the American College of Cardiology, J AM Coll Cardiol* 2003;41. (Abstract)
86. Col J, Renkin J, Prioux D, Yeung R, Deceuninck P, Michel X, Foding Deffo B, Schroeder E, Haine E, Van den Heuvel P, Ragosta M, Lamas GA, Hochman J.

International patterns in the care of acute MI patients in the occluded artery trial (OAT): characteristics of 1835 screened patients. *Acta Cardiol* 2003;58(1):54.

87. Renkin J, Col J, Markovitch O, de Meester A, Deceuninck P, Michel X, Taeymans Y, Van den Heuvel P, Castadot M, Forman S, Lamas GA, Hochman J. Patient and Physician Preferences for Therapy of an Occluded Infarct-Related Artery Late After Myocardial Infarction. Observations from the Registry of the Occluded Artery Trial (OAT) *Acta Cardiol* 2003; 58(1):81.
88. Ragosta M, Maggioni AP, Michalis LK, Lang I, Carvalho AC, Lobo-Grudzien K, Delin G, Reis G, Merciar P, Forman S, Lamas GA, Hochman JS, on behalf of OAT Investigators, Charlottesville, VA. International patterns in the care of acute myocardial infarction patients in the Occluded Artery Trial (OAT): Characteristics of 1,835 screened patients. *J Am Coll Cardiol* 2003;41:377A.
89. Abreu P, Thomas B, Nédio M, Ferreira R, Forman S, Lamas G, Hochman JS. Preferência Do Doente E Do Médico Para O Tratamento Tardio Da Artéria Ocluída Relacionada Com O Enfarte. Observações Do Registo Do Estudo Da Artéria Ocluída (OAT) *Rev Port Card* 2003; 22 (Suppl I):59
90. Abreu P, Thomas B, Nédio M, Ferreira R, Forman S, Lamas G, Hochman JS. Padrões Clínicos Internacionais Em Doentes Com Enfarte Agudo Do Miocárdio No Estudo Da Artéria Ocluída (Oat): Características De 2399 Doentes Incluídos. *Rev Port Card* 2003; 22 (Suppl I):58
91. Lowe R, Lamas GA, Kandzari DE, Tchong JE, Knatterud G, Mancini GBJ, White H, Col J, Dzavik V, Forman S, Hochman J, Buller CE. Does Ventricular Geometry Simply Measure Ejection Fraction? An Analysis from the Occluded Artery Trial (OAT). *Heart* 2003; 89 (Suppl 1): 27.
92. Carvalho A, Lima V, Gottschall C, Saad J, Caramori P, Machado M, Sarmiento-Leite R, Forman S, Lamas GA, Hochman JS. International patterns in the care of acute MI patients in the Occluded Artery Trial (OAT): Characteristics of 2423 screened patients. *Arq Bras Cardiol* 2003; 81(Supl I):22
93. Carvalho A, Fernandes R, Caramori P, Machado M, Reis G, Marin-Neto J, Lima M, Forman S, Lamas G, Hochman J. Patient & Physician Preferences for Therapy of an Occluded Infarct-Related Artery Late After Myocardial Infarction. Observations from the Occluded Artery Trial (OAT) Registry. *Arq Bras Cardiol* 2003; 81(Supl I):38
94. Nava G, Wu D, Bassuk J, Lamas GA, Kurlansky P, Adams JA. Echocardiographic Evaluation of Left Ventricular Function after Periodic Acceleration (pGz) and Conventional Cardiopulmonary Resuscitation, in a Porcine Model. *Circulation* 2003;107:1942A
95. Velazquez EJ, Jones WS, Smith WT, Kober L, Kilaru R, Rittenhouse LM, Granger CB, Weaver W, Lamas G, Zelenkofske SL, Aylward PE, Henis M, Swedberg K, Pfeffer MA, Van de Werf F, Rouleau J, Califf RM. International Assessment of Atrial Fibrillation in Myocardial Infarction: The VALIANT Registry. *Circulation* 2003;107:1961A

96. Rinfret S, Cohen DJ, Lamas GA, Fleischmann KE, Weinstein MC, Orav J, Schron E, Lee KL, Goldman L. Cost-Effectiveness of Dual-Chamber Versus Ventricular Pacing from the Mode Selection Trial (MOST) in Sinus-Node Dysfunction. *Circulation* 2003;107:3499A
97. Ayala F, Ugalde H, Fajuri A, Martínez A, Villablanca S, Bellet A, Forman S, Lamas G, Hochman J. Oclusión coronaria total persistente despues de infarto del miocardio. Estudio de la Arteria Ocluída (Occluded Artery Trial) Qué desean los pacientes? Observaciones de un Registro. *Revista Chilena de Cardiología* 2003; 22:3
98. Fleischmann KE, Orav EJ, Lamas GA, Mangione CM, Schron E, Goldman L. Pacing mode and quality of life in the Mode Selection Trial. *J Am Coll Cardiol* 2004;43:147A.
99. Lamas GA, Ackermann A, Hollar D, Kurlansky P, Vita J, Hennekens CH. Chelation therapy for patient with coronary heart disease: Findings from the Pilot to Assess Chelation Therapy. *J Am Coll Cardiol* 2004;43:252A.
100. Kenchaiah S, Pfeffer MA, St. John Sutton M, Plappert T, Rouleau JL, Lamas GA, Sasson Z, Parker JO, Geltman EM, Braunwald E, Solomon SD. Antecedent hypertension and the risk of subsequent left ventricular remodeling after acute myocardial infarction: Insights from the Survival and Ventricular Enlargement Trial. *J Am Coll Cardiol* 2004;43:511A.
101. Fleischmann KE, Orav EJ, Lamas GA, Mangione CM, Schron EB, Goldman L. Atrial fibrillation and quality of life after pacemaker implantation for sick sinus syndrome. *Heart Rhythm* 2004;1(1S):S276-S277.
102. Hellkamp AS, Lee KL, Sweeney MO, Link MS, Lamas GA. Treatment crossovers did not affect randomized treatment comparisons in the Mode Selection Trial (MOST). *Heart Rhythm* 2004;1(1S):S149.
103. Shukla HH, Hellkamp AS, James EA, Flaker GC, Lee KL, Sweeney MO, Lamas GA, For the MOST Investigators. Heart failure is more common in pacemaker patients with a prolonged paced QRS duration. *Heart Rhythm* 2004;1(1S):S116.
104. Montanez A, Hennekens CH, Zebede J, Lamas GA MD. Pacing in vasovagal syncope: qualitative overview and meta-analysis of the randomized trials. *Heart Rhythm* 2004;1(1S):S55.
105. Adams JA, Nava G, Wu D, Bassuk J, Arias J, Lamas G, Kurlansky P. Prostaglandins are Involved in the Early Myocardial Protective Effect Observed after Periodic Acceleration-CPR (pGz-CPR). *Circulation* 2004; 110:1632A
106. Reynolds HR, Ramanathan K, Lamas GA, Forman S, Anagnostopoulos CE, Rankin JM, Carere RG, Hochman JS, Buller CE. LV Geometry and Mitral Regurgitation in Patients with Persistent Total Occlusion of the Infarct Artery in OAT. *Circulation* 2004; 110:3057A.
107. Lewis EF, Lamas GA, McMurray J, Carisson J, Granger C, Klap ME, O'Meara E, Swedberg K, Rouleau JL, Pfeffer MA. Quality of life among patients with heart failure

and preserved ejection fraction versus low ejection fraction: Does ejection fraction matter? *J Am Coll Cardiol* 2005;45:169A.

108. Sweeney MO, Nsah E, McGrew F, Pham T, Koullick M, Pruett K, Sahr DM, Lamas GA, The SAVE PACe Investigators and Medtronic, Inc. Reduction in ventricular pacing and its long-term clinical outcomes: Preliminary results of the SAVE PACe trial. *Heart Rhythm* 2005;2(5S):S322.
109. Hussein SJ, Lamas GA, Knight DJ, Mianulli MJ, Sweeney MO, Mark DB. Clinical significance of chronotropic incompetence in 872 ADEPT patients. *Heart Rhythm* 2005;2(5S):S285-S286.
110. Kukreja S, Lamas GA, Knight JD, Mianulli MJ, Clapp-Channing NE, Mark DB. Predictors of quality of life in 872 paced patients with chronotropic incompetence in the ADEPT study. *Heart Rhythm* 2005;2(5S):S285.
111. Hussein SJ, Carrillo-Jimenez R, Hellkamp AS, Montanez A, Flaker GC, Zebede J, Lee KL, Lamas GA. Antiarrhythmic drug use and mortality in pacemaker patients with sinus node dysfunction. *Heart Rhythm* 2005;2(5S):S206.
112. Peña JL, Hussein SJ, Lamas GA, Sweeney MO, Mianulli MJ, Knight DJ, Mark DB. A comparison of clinical events in a randomized clinical trial of DDDR versus DDD pacing. *Heart Rhythm* 2005;2(5S):S127-S128.
113. Sweeney MO, Knight JD, Mark DB, Mianulli MJ, Lamas GA. Incidence, mechanisms and duration of inappropriate mode switching in ADEPT (advanced elements of pacing trial). *Heart Rhythm* 2005;2(5S):S41.
114. Wu D, Bassuk J, Arias J, Kurlansky P, Lozano H, Lamas G, Adams JA. Differential Role of Nitric Oxide Synthase Isoforms on Cardiopulmonary Resuscitation with Periodic Acceleration (pGz) in Pigs. *Circulation* 2005; 112:1621A.
115. Heimowitz TB, Zagler A, Lamas GA, Vignola PA, Solomon SD, Pfeffer MA. Changes in Ejection Fraction in Long-Term Survivors Post-Myocardial Infarction: Relevance to Indications for Defibrillator Implantation. *Circulation* 2005; 112:2581A.
116. Adams JA, Lozano H, Wu D, Jorge B, Arias J, Lamas GA, Kurlansky P. The Impact of COX-1 and COX -2 Inhibition on Cardiopulmonary Resuscitation in Swine. *ReSS* 2005; 12A.
117. Jorapur V, Steigen T, Buller CE, Dzavik V, Webb J, Strauss BH, Yeoh E, Kurray P, Sokalski L, Machado M, Forman S, Lamas GA, Hochman JS, Mancini GJ. Clinical and coronary angiographic correlates of Myocardial Perfusion Grade following late mechanical reperfusion of occluded infarct-related arteries post-myocardial infarction – a Total Occlusion Study of Canada-2 substudy. *Circulation* 2006; 114:1748A.
118. Jorapur V, Sadowski Z, Reynolds HR, Carvalho AC, Buller CE, Rankin J, Renkin J, Steg PG, White H, Vozzi C, Balcells E, Ragosta M, Martin CE, Tamis-Holland JE, Srinivas V, Wharton W, Abramsky S, Mon AC, Barton B, Lamas GA, Hochman JS. Chronic kidney disease, ejection fraction and heart failure in patients with occluded

infarct-related arteries post-myocardial infarction: data from the Occluded Artery Trial. *Circulation* 2006; 114:1995A.

119. Steigen T, Jorapur V, Buller CE, Dzavik V, Cardona M, Almond D, Brass N, Burton J, Zurakowski A, Forman S, Lamas GA, Hochman JS, Mancini GJ. Association of Myocardial Perfusion Grade after late infarct reperfusion with baseline indices of global LV function, analysis from the Total Occlusion Study of Canada-2. *Circulation* 2006; 114:2465A.
120. Bassuk J, Wu D, Lozano H, Arias J, Kurlansky P, Lamas G, Adams J. Non Selective Cyclooxygenase Inhibition Prior To Periodic Acceleration (pGz) Cardiopulmonary Resuscitation (CPR) in a Porcine Model of Ventricular Fibrillation. *ReSS* 2006; 45A.
121. Adams JA, Wu D, Bassuk J, Lozano H, Arias J, Kurlansky P, Lamas G. Differential Effect of NOS Inhibition on CPR Outcomes in Pigs. *ReSS* 2006; 102A.
122. Lozano HF, Hellkamp AS, Lee KL, Montanez A, Flaker G, Lamas GA. Ace-inhibitors did not prevent atrial fibrillation in the Pacemaker Mode Selection Trial. *J Am Coll Cardiol* 2007;49:12A.
123. Pearte CA, Udelson JE, Kruk M, Reynolds HR, Ruzyllo W, Sadowski Z, Teresinska A, Bychowiec B, Höchtl T, Marin-Neto JA, Cohen EA, Busz-Papiez B, Caramori P, Adlbrecht C, Kimmelstiel C, Buller CE, Forman S, Lamas GA, Hochman JS. Infarct, size, viability, and correlates in patients presenting with a persistent total occlusion of the infarct-related artery 3-28 days post myocardial infarction: An Occluded Artery Trial (OAT) substudy. *J Am Coll Cardiol* 2007;49:199A.
124. Jorapur V, Lamas GL, Morcillo L, Guala P, Vignola PA, Smith SC, Flaker GC, Solomon SD, Pfeffer MA. Coronary and left ventricular angiographic correlates of chronic kidney disease following acute myocardial infarction – data from the Survival And Ventricular Enlargement (SAVE) Trial. *J Am Coll Cardiol* 2007;49:353A.
125. Sweeney MO, Bank AJ, Nsah E, Koullick M, Zeng QC, Hettrick T, Sheldon T, Lamas GA. Conventional Dual Chamber Pacing Compared with a Strategy to Minimize Ventricular Pacing in Sinus Node Disease. *Heart Rhythm* 2007 Late Breaking Trial.
126. Buller CE, Mancini GB, Dzavik V, Pfisterer ME, Rankin JM, Carere RG, Michalis LK, Renkin J, Forman SA, Areu PF, Lamas, GA, Hochman JS. PCI Failure in the Occluded Artery Trial (OAT): Frequency, Mechanisms, and Outcome. *Circulation* 2007; 116:1934.
127. Buller CE, Dzavik V, Forman SA, Ruzyllo W, Buszman PE, Michalis LK, Mancini J, Renkin J, Pfisterer ME, Thomas B, Lamas GA, Hochman JS. Similar long-term outcomes after PCI success, PCI failure, and no PCI in the Occluded Artery Trial (OAT). *Circulation* 2007; 116:2393.
128. Adams JA, Bassuk J, Wu H, Arias J, Wu D, Jorapur V, Benenstein R, Lamas G, Kurlansky P. Post treatment with periodic acceleration (pGz) after cardiac arrest decreases acute post resuscitation myocardial stunning in swine. *Circulation* 2007; 116:2633A.

129. Udelson JE, Pearte CA, Kimmelstiel CD, Kruk M, Teresinska A, Bychowiec B, Marin-Neto JA, Höchtel T, Cohen EA, Caramori P, Busz-Papiez B, Adlbrecht C, Sadowski ZP, Ruzylo W, Forman SA, Kinan DJ, Lamas GA, Hochman JS. The Occluded Artery Trial (OAT) viability ancillary study (OAT-NUC): influence of infarct zone viability on left ventricular remodeling after PCI vs. medical therapy alone. *Circulation* 2007; 116:2810A.
130. Kruk M, Kadziela J, Sadowski ZP, Barton BA, Mark DB, Forman SA, Reynolds HR, Maggioni AP, Leor J, Webb JG, Kapeliovich M, Marin-Neto JA, White HD, Lamas GA, Hochman JS. Predictors of outcome and the lack of effect of PCI across the risk strata in patients with persistent total occlusion after myocardial infarction: results from the Occluded Artery Trial (OAT). *Circulation* 2007; 116:2811A.
131. White HD, Steg PG, Dzavik V, Menon V, Reynolds HR, Carvalho AC, Barton BA, Cantor WJ, Kruk M, Martin CE, Pearte CA, Knatterud GL, Lamas GA, Hochman JS. Predictors of reinfarction following PCI or medical management in patients with persistent total occlusion after myocardial infarction: results from the Occluded Artery Trial (OAT). *Circulation* 2007; 116:2812A.
132. Lang I, Forman SA, Maggioni AP, Ruzylo W, Vozzi C, Renkin J, Steg PG, Hernandez-Gardia JM, Zmudka K, Jimenez-Navarro M, Sopko G, Lamas GA, Hochman JS. Causes of death in early MI survivors with persistent vessel occlusion: results from the Occluded Artery Trial (OAT). *Circulation* 2007; 116:2813A.
133. Buller CE, Rankin JM, Renkin J, Carere RG, Dzavik V, Ruzylo W, Forman SA, Buszman PE, Mancini GB, Abreu PF, Lamas GA, Hochman JS. Did early hazard of PCI offset late benefit in the Occluded Artery Trial (OAT)? *Circulation* 2007; 116:2986A.
134. Cantor WJ, Lamas GA, Nikolsky E, Pearte CA, Srinivas VS, Forman SA, Menon V, Ross JR, Baptista SB, Meciar M, Sadowski Z, Hochman JS. Impact of Stress Testing Prior to PCI or Medical Management on Outcomes of Patients With Persistent Total Occlusion After Myocardial Infarction: Analysis from the Occluded Artery Trial (OAT). *J Am Coll Cardiol* 2008;51:A191.
135. Menon V, Pearte CA, Buller CE, Steg G, Forman SA, White HD, Marino PN, Katritsis DG, Caramori P, Lasevitch R, Loboz-Grudzien K, Zurakowski A, Lamas GA, Hochman JS. Lack of Benefit with PCI for Total Occlusions in Stable Patients Following Myocardial Infarction is Time Independent: Results from the Occluded Artery Trial (OAT). *J Am Coll Cardiol* 2008;51:A201.
136. Steg G, Kerner A, Buller CE, Forman SA, White HD, Carvalho AC, Reynolds HR, Fridrich V, Cohen EA, Mancini J, Lamas GA, Hochman JS. Collateral Flow to the Occluded Infarct-related Artery is Associated with a Lower Rate of Heart Failure in the Occluded Artery Trial (OAT). *J Am Coll Cardiol* 2008;51:A215.
137. Devlin GP, Mark DB, Lamas GA, Carvalho AC, Dzavik V, Forman SA, Vozzi CR, Ragosta M, Rankin JM, Caramori P, Sopko G, Balcells E, Leor J, Barton BA, Hochman JS. Routine PCI Improves Short but not Long Term Angina Status in Patients with an Occluded Infarct Artery: Results from the Occluded Artery Trial (OAT). *J Am Coll Cardiol* 2008;51:A222.

138. Sweeney M, Hettrick D, Sheldon T, Zeng Q, Lamas GA, SAVE PACe Investigators; Minimized Ventricular Pacing Reduces Atrial Tachyarrhythmia Burden in Pacemaker Patients with Sinus Node Dysfunction: Further Results of the SAVE PACe trial. *Heart Rhythm*; 2008; AB13-4.
139. Elkayam L, Koehler J, Sheldon T, Rosenthal L, Lamas GA. The Influence of Atrial and Ventricular Pacing on the Incidence of Atrial Fibrillation: A Meta Analysis. *Heart Rhythm*; 2008; PO4-55.
140. Lamas GA, Balu S, Spalding J, Lee W, Wang Q, Pashos C, Management and Clinical Consequence of Atrial Fibrillation in Medicare Patients. *Heart Rhythm*; 2008; PO6-20.
141. Adams J, Arias J, Bassuk J, Wu H, Uryash A, Webster K, Lamas GA, Kurlansky P; Periodic Acceleration (pGz) Preconditioning in Swine Increases Endothelial Derived NO and Phosphorylated eNOS via Akt Pathway; *Circulation*. 2008;118:S_1448.
142. Overgaard C, Buller C, Maggioni A, Leor J, Ruzyllo W, Burton J, Reis G, Liu L, Devlin G, Banasiak W, Lamas GA, Hochman J, Dzavik V; Late Clinical Outcomes of Diabetic Patients Randomized in the Occluded Artery Trial (OAT); *Circulation*. 2008;118:S_661.
143. Reynolds H, Tamis-Holland J, Kronsberg S, Steg P, Carvalho A, Lobo-Grudzien K, Kruk M, Sopko G, Ruzyllo W, Pearte C, Forman S, Lamas GA, Hochman J; Sex Differences in Outcomes after Myocardial Infarction with Persistent Total Occlusion of the Infarct Artery: Analysis of the Occluded Artery Trial; *Circulation*. 2008;118:S_967.
144. Soran OZ, Piña IL, Lamas GA, Kelsey SF, Selzer F, Pilotte J, Feldman AM. Impact of a Sophisticated Computer Based Telephonic Heart Failure Monitoring System on Quality-of-Life in Patients With Heart Failure. *J Am Coll Cardiol* 2008;51:A248.
145. Soran OZ, Feldman A, Pina IL, Lamas, GA, Kelsey S, Selzer S, Pilotte J, Lave, J. Cost of Medical Services in Older Patients With Heart Failure: Those Receiving Enhanced Monitoring Using a Computer-Based Telephonic Monitoring System Compared With Those in Usual Care: The Heart Failure Home Care Trial. *J Card Fail*. Published online July 20, 2010.
146. Santana O, Reyna J, Elkayam LU, Funk M, Lamas GA, Lamelas J. Outcomes of Minimally Invasive Valve Surgery in Patients with an Ejection Fraction $\leq 30\%$. *J Heart Dis*; 2010; 7; A24.
147. Hochman JS, Reynolds HR, Dzavik V, Buller CE, Ruzyllo W, Sadowski ZP, Maggioni AP, Carvalho AC, Rankin JM, Goldberg S, Forman SA, Mark DB, Lamas GA, and OAT investigators. Persistent Lack of Benefit of Late Revascularization of the Occluded Coronary Artery Post- MI- The Occluded Artery Trial (OAT) Long Term Results; *Circulation*. 2010; 122:A13116.
148. Lamelas J, Sarria A, Santana O, Pineda A, Lamas GA. Short-term Outcomes of Minimally Invasive Valve Surgery versus Median Sternotomy in Patients ≥ 75 years of age with Isolated Valve Lesions. *J Heart Dis*; 2010; 7; A25.

149. Freixa X, Forman SA, Rankin JM, Buller CE, Cantor WJ, Ruzylo W, Lamas GA, Hochman JS, Dzavik V. 6-Year Outcomes Of Patients Treated With DES, BMS or Medical Therapy in the OAT Trial; *J Am Coll Cardiol*. 2011; 57:E1833.
150. Hochman JS, Hastings R, Reynolds HR, Dzavik V, Mikas D, Michalis LK, Schiele F, Forman SA, Lamas GA. Renal Insufficiency In Patients With A Total Occlusion Of A Coronary Artery After Myocardial Infarction; *J Am Coll Cardiol*. 2010; 55:A119.
151. Taya Glotzer, Gervasio Lamas, Anne S Hellkamp, Kerry L. Lee. CHADS2 and CHA2DS2- VASc scores are Predictive of Adverse Cardiovascular Outcomes in All Patients, Not Just Those with a Diagnosis of AF: an Analysis of the 2010 Patients from the MOST Trial; *Circulation*. 2013;128:A10999
152. Escolar E, Lamas GA, Mark DB, Ouyang P, Magziner A, Boineau R, Miranda R, Goertz C, Rosenberg Y, Nahin RL, Nahas R, Lewis EF, Lindabald L, Lee KL. Clinical Benefit of EDTA Chelation Therapy in Patients with Diabetes in the Trial to Assess Chelation Therapy (TACT); *Circulation*. 2013;128:A11546
153. Vidi VD, Reyna J, Santana O, Parise H, Lamelas J, Lamas GA. A Simple Risk Prediction Score for Patients Undergoing Minimally Invasive Valve Surgery; *J Am Coll Cardiol*. 2013; 61: E1603.
154. Holmqvist F, Hellkamp AS, Lee KL, Lamas GA, Daubert JP. Adverse Effects of First-Degree-AV-Block in Patients with Sinus Node Dysfunction: Data from the Mode Selection Trial; *Circulation*. 2013; 128:A12149.
155. Lamas GA, Nahin RL, Lindblad L, Goertz C, Boineau R, Chappell T, Flaker G, Rozema T, Born T, Stylianou M, Lewis EF, Mark DB, Lee KL. Clinical Benefit of EDTA- based Chelation Therapy and High-dose Oral Multivitamins and Multiminerals in TACT- an Expanded Comparison of 2 Factorial Groups; *Circulation*. 2013; 128:A11054.
156. Pineda AM, Santana O, Bergoderi MC, Mihos C, Beohar N, Lamas GA, Lamelas J. Long-Term Outcomes Of A Hybrid Approach Of Percutaneous Coronary Intervention Followed By Minimally Invasive Valve Surgery; *J Am Coll Cardiol*. 2014; 63:A1938.
157. Peguero J, Podesta C, Issa O, Santana O, Jacobson J, Lamas GA. CHAD2DS2VASC Score Is Superior To Atrial Fibrillation In Predicting Post- Operative Ischemic Stroke In Patients Undergoing Cardiothoracic Surgery; *J Am Coll Cardiol*. 2014; 63:A1953.
158. Lewis EF, Lamas GA, Mark D, Rosenberg Y, Boineau R, Roberts RS, Goertz C, Stylianou M, Lindblad L, Lee K. Differential Outcomes With Chelation Therapy Among Patients With Anterior Versus Non-Anterior Myocardial Infarction: A Tact Substudy; *J Am Coll Cardio*. 2014; 63: A1565.
159. Ouyang P, Lamas GA, Nahin R, Gallup D, Boineau R, Rosenberg Y, Mark D, Goertz C, Lee K. Effect Of Chelation Therapy On Cardiovascular Events By Chronic Kidney Disease Stage: Data From The Trial To Assess Chelation Therapy(TACT); *J Am Coll Cardiol*. 2014; 63: A1537.

160. Lamas GA, Escolar E, Boineau R, Nahin R, Goertz C, Mark D, Golden P, Merritt D, Rosenberg Y, Lindblad L, Lee K. Clinical Benefit of Chelation Therapy in Post-MI Patients with Diabetes and Peripheral Artery Disease. *Circulation*. 2014;130:A16630.
161. Lamas Ga, Escolar E, Boineau R, Nahin R, Goertz C, Mark D, Rosenberg Y, Lindblad L, Lee K. Graded Benefit of EDTA Chelation in Post-MI Patients with Diabetes Treated with Different Hypoglycemic Strategies. *Circulation*. 2014;130:A18819.
162. Drisko J, Alexander K, Roberts R, Chappell T, Lee K, Boineau R, Mark D, Nahin R, Goertz C, Rosenberg Y, Lamas GA. Post-myocardial infarction treatment with edetate disodium was safe in the Trial to Assess Chelation Therapy. *Circulation*. 2015; 132: A10466.
163. Lamas GA, Guarneri E, Mark D, Boineau R, Bradley R, Goertz C, Rosenberg Y, Nahin R, Lewis E, Drisko J, Lindblad L, Lee K. Effect Of High-Dose Oral Multi-Vitamins And Minerals In Patients Not Treated With Statins In The Trial To Assess Chelation Therapy. *Circulation*. 2015; 132: A10476.
164. Lee K, Roberts R, Mark D, Al-Khalidi H, Boineau R, Rosenberg Y, Stylianou M, Lamas GA. Behind the looking glass: Comparing time to first event versus multiple events analyses in a post-myocardial infarction clinical trial. *Circulation*. 2015; 132: A16911.
165. Arenas I, Navas-Acien A, Lamas GA. Enhanced Vasculotoxic Metal Excretion in Post-Myocardial Infarction Patients Receiving Edetate Disodium-Based Infusion. *J Am Coll Cardiol*. 2016;67(13_S):2125-2125.
166. Arenas I, Ergui I, Lamas GA, Navas-Acien A. Urinary Lead Excretion Urinary Lead Excretion Correlates With Overall Toxic Metal Excretion in Patients With Coronary Artery Disease: A Sentinel Biomarker? *J Am Coll Cardiol*. 2017; 69(11):251.
167. Arenas IA, Ergui I, Lamas GA. Safety of Chelation Therapy with EDTA in Patients with Critical Limb Ischemia: A Pilot Trial of Limb Preservation in Diabetic Patients. *AHA/ATVB/PVD*. 2017;37:A494.
168. Arenas IA, Ujueta F, Diaz D, Navas-Acien A, Beasley A, Yates T, Olivieri B, Lamas GA. Pilot Study of Edetate Disodium-Based Chelation in Diabetics with Critical Limb Ischemia. *American Heart Association*. 2018;138:A13005
169. Ujueta F, Arenas IA, Navas-Acien A, Yates T, Olivieri B, Beasley R, Lamas GA. Reducing body burden of lead is associated with resolution of critical limb ischemia. *Amputation Prevention Symposium (AMP)*. Chicago, IL, August 2019.
170. Navas-Acien A, Alam Z, Ujueta F, Domingo-Relloso A, Lamas GA. Urinary metal levels after repeated chelation with edetate disodium: Additional evidence in support of metals as cardiovascular risk factors. *AHA Epidemiology Conference*. Arizona. March 2020.

F. Audiovisual/Media- N/A